{
    "abstract": "Background: West Nile virus (WNV) is the most common mosquito-borne infection in the United States. HydroVax-001 WNV is a hydrogen peroxide inactivated, whole virion (WNV-Kunjin strain) vaccine adjuvanted with aluminum hydroxide. Methods: We performed a phase 1, randomized, placebo-controlled, double-blind (within dosing group), dose escalation clinical trial of the HydroVax-001 WNV vaccine administered via intramuscular injection. This trial evaluated 1 mcg and 4 mcg dosages of HydroVax-001 WNV vaccine given intramuscularly on day 1 and day 29 in healthy adults. The two dosing groups of HydroVax-001 were enrolled sequentially and each group consisted of 20 individuals who received HydroVax-001 and 5 who received placebo. Safety was assessed at all study days (days 1, 2, 4 and 15 post dose 1, and days 1, 2, 4, 15, 29, 57, 180 and 365 post dose 2), and reactogenicity was assessed for 14 days after administration of each dose. Immunogenicity was measured by WNV-specific plaque reduction neutralization tests (PRNT50) in the presence or absence of added complement or by WNV-specific enzyme-linked immunosorbent assays (ELISA). Results: HydroVax-001 was safe and well-tolerated as there were no serious adverse events or concerning safety signals. At the 1 mcg dose, HydroVax-001 was not immunogenic by PRNT50 but elicited up to 41% seroconversion by WNV-specific ELISA in the per-protocol population (PP) after the second dose. At the 4 mcg dose, HydroVax-001 elicited neutralizing antibody responses in 31% of the PP following the second dose. In the presence of added complement, PRNT50 seroconversion rates increased to 50%, and 75% seroconversion was observed by WNV-specific ELISA. Conclusions: The HydroVax-001 WNV vaccine was found to be modestly immunogenic and well-tolerated at all dose levels.",
    "bib_entries": {
        "b0005": {
            "authors": [
                {
                    "first": "Denis",
                    "initial": "D.",
                    "last": "Nash"
                },
                {
                    "first": "Farzad",
                    "initial": "F.",
                    "last": "Mostashari"
                },
                {
                    "first": "Annie",
                    "initial": "A.",
                    "last": "Fine"
                },
                {
                    "first": "James",
                    "initial": "J.",
                    "last": "Miller"
                },
                {
                    "first": "Daniel",
                    "initial": "D.",
                    "last": "O'Leary"
                },
                {
                    "first": "Kristy",
                    "initial": "K.",
                    "last": "Murray"
                },
                {
                    "first": "Ada",
                    "initial": "A.",
                    "last": "Huang"
                },
                {
                    "first": "Amy",
                    "initial": "A.",
                    "last": "Rosenberg"
                },
                {
                    "first": "Abby",
                    "initial": "A.",
                    "last": "Greenberg"
                },
                {
                    "first": "Margaret",
                    "initial": "M.",
                    "last": "Sherman"
                },
                {
                    "first": "Susan",
                    "initial": "S.",
                    "last": "Wong"
                },
                {
                    "first": "Marcelle",
                    "initial": "M.",
                    "last": "Layton"
                }
            ],
            "doi": "10.1056/NEJM200106143442401",
            "firstpage": "1807",
            "issn": "00284793",
            "lastpage": "1814",
            "pmid": "11407341",
            "pub_year": 2001,
            "title": "The outbreak of West Nile virus infection in the New York City area in 1999",
            "volume": "344"
        },
        "b0010": {
            "authors": [
                {
                    "first": "Lyle R.",
                    "initial": "L.R.",
                    "last": "Petersen"
                },
                {
                    "first": "Edward B.",
                    "initial": "E.B.",
                    "last": "Hayes"
                }
            ],
            "doi": "10.1016/j.mcna.2008.07.004",
            "firstpage": "1307",
            "issn": "00257125",
            "lastpage": "1322",
            "pmid": "19145778",
            "pub_year": 2008,
            "title": "West Nile Virus in the Americas",
            "volume": "92"
        },
        "b0015": {
            "authors": [
                {
                    "first": "James J.",
                    "initial": "J.J.",
                    "last": "Sejvar"
                },
                {
                    "first": "Maryam B.",
                    "initial": "M.B.",
                    "last": "Haddad"
                },
                {
                    "first": "Bruce C.",
                    "initial": "B.C.",
                    "last": "Tierney"
                },
                {
                    "first": "Grant L.",
                    "initial": "G.L.",
                    "last": "Campbell"
                },
                {
                    "first": "Anthony A.",
                    "initial": "A.A.",
                    "last": "Marfin"
                },
                {
                    "first": "Jay A.",
                    "initial": "J.A.",
                    "last": "Van Gerpen"
                },
                {
                    "first": "Aaron",
                    "initial": "A.",
                    "last": "Fleischauer"
                },
                {
                    "first": "A. Arturo",
                    "initial": "A.A.",
                    "last": "Leis"
                },
                {
                    "first": "Dobrivoje S.",
                    "initial": "D.S.",
                    "last": "Stokic"
                },
                {
                    "first": "Lyle R.",
                    "initial": "L.R.",
                    "last": "Petersen"
                }
            ],
            "doi": "10.1001/jama.290.4.511",
            "firstpage": "511",
            "issn": "00987484",
            "lastpage": "515",
            "pmid": "12876094",
            "pub_year": 2003,
            "title": "Neurologic Manifestations and Outcome of West Nile Virus Infection",
            "volume": "290"
        },
        "b0020": {
            "authors": [
                {
                    "first": "Lyle R.",
                    "initial": "L.R.",
                    "last": "Petersen"
                },
                {
                    "first": "Aaron C.",
                    "initial": "A.C.",
                    "last": "Brault"
                },
                {
                    "first": "Roger S.",
                    "initial": "R.S.",
                    "last": "Nasci"
                }
            ],
            "doi": "10.1001/jama.2013.8042",
            "firstpage": "308",
            "issn": "00987484",
            "lastpage": "315",
            "pmid": "23860989",
            "pub_year": 2013,
            "title": "West Nile virus: Review of the literature",
            "volume": "310"
        },
        "b0025": {
            "authors": [
                {
                    "first": "Mimi",
                    "initial": "M.",
                    "last": "Emig"
                },
                {
                    "first": "Douglas J.",
                    "initial": "D.J.",
                    "last": "Apple"
                }
            ],
            "doi": "10.1086/380458",
            "firstpage": "289",
            "issn": "10584838",
            "lastpage": "292",
            "pmid": "14699464",
            "pub_year": 2004,
            "title": "Severe West Nile Virus Disease in Healthy Adults",
            "volume": "38"
        },
        "b0030": {
            "authors": [
                {
                    "first": "James J.",
                    "initial": "J.J.",
                    "last": "Sejvar"
                }
            ],
            "doi": "10.1086/518281",
            "firstpage": "1617",
            "issn": "10584838",
            "lastpage": "1624",
            "pmid": "17516407",
            "pub_year": 2007,
            "title": "The long-term outcomes of human West Nile virus infection",
            "volume": "44"
        },
        "b0035": {
            "authors": [
                {
                    "first": "Luisa",
                    "initial": "L.",
                    "last": "Barzon"
                },
                {
                    "first": "Monia",
                    "initial": "M.",
                    "last": "Pacenti"
                },
                {
                    "first": "Giorgio",
                    "initial": "G.",
                    "last": "Pal\u00f9"
                }
            ],
            "doi": "10.1586/eri.13.34",
            "firstpage": "479",
            "issn": "14787210",
            "lastpage": "487",
            "pmid": "23627854",
            "pub_year": 2013,
            "title": "West Nile virus and kidney disease",
            "volume": "11"
        },
        "b0040": null,
        "b0045": {
            "authors": [
                {
                    "first": "Ian J.",
                    "initial": "I.J.",
                    "last": "Amanna"
                },
                {
                    "first": "Mark K.",
                    "initial": "M.K.",
                    "last": "Slifka"
                }
            ],
            "doi": "10.1586/14760584.2014.906309",
            "firstpage": "589",
            "issn": "14760584",
            "lastpage": "608",
            "pmid": "24689659",
            "pub_year": 2014,
            "title": "Current trends in West Nile virus vaccine development",
            "volume": "13"
        },
        "b0050": {
            "authors": [
                {
                    "first": "Anna P.",
                    "initial": "A.P.",
                    "last": "Durbin"
                },
                {
                    "first": "Peter F.",
                    "initial": "P.F.",
                    "last": "Wright"
                },
                {
                    "first": "Amber",
                    "initial": "A.",
                    "last": "Cox"
                },
                {
                    "first": "Wangeci",
                    "initial": "W.",
                    "last": "Kagucia"
                },
                {
                    "first": "Daniel",
                    "initial": "D.",
                    "last": "Elwood"
                },
                {
                    "first": "Susan",
                    "initial": "S.",
                    "last": "Henderson"
                },
                {
                    "first": "Kimberli",
                    "initial": "K.",
                    "last": "Wanionek"
                },
                {
                    "first": "Jim",
                    "initial": "J.",
                    "last": "Speicher"
                },
                {
                    "first": "Stephen S.",
                    "initial": "S.S.",
                    "last": "Whitehead"
                },
                {
                    "first": "Alexander G.",
                    "initial": "A.G.",
                    "last": "Pletnev"
                }
            ],
            "doi": "10.1016/j.vaccine.2013.07.064",
            "firstpage": "5772",
            "issn": "0264410X",
            "lastpage": "5777",
            "pmid": "23968769",
            "pub_year": 2013,
            "title": "The live attenuated chimeric vaccine rWN/DEN4\u03b430 is well-tolerated and immunogenic in healthy flavivirus-na\u00efve adult volunteers",
            "volume": "31"
        },
        "b0055": {
            "authors": [
                {
                    "first": "Thomas P.",
                    "initial": "T.P.",
                    "last": "Monath"
                },
                {
                    "first": "Jian",
                    "initial": "J.",
                    "last": "Liu"
                },
                {
                    "first": "Niranjan",
                    "initial": "N.",
                    "last": "Kanesa-Thasan"
                },
                {
                    "first": "Gwendolyn A.",
                    "initial": "G.A.",
                    "last": "Myers"
                },
                {
                    "first": "Richard",
                    "initial": "R.",
                    "last": "Nichols"
                },
                {
                    "first": "Alison",
                    "initial": "A.",
                    "last": "Deary"
                },
                {
                    "first": "Karen",
                    "initial": "K.",
                    "last": "McCarthy"
                },
                {
                    "first": "Casey",
                    "initial": "C.",
                    "last": "Johnson"
                },
                {
                    "first": "Thomas",
                    "initial": "T.",
                    "last": "Ermak"
                },
                {
                    "first": "Sunheang",
                    "initial": "S.",
                    "last": "Shin"
                },
                {
                    "first": "Juan",
                    "initial": "J.",
                    "last": "Arroyo"
                },
                {
                    "first": "Farshad",
                    "initial": "F.",
                    "last": "Guirakhoo"
                },
                {
                    "first": "Jeffrey S.",
                    "initial": "J.S.",
                    "last": "Kennedy"
                },
                {
                    "first": "Francis A.",
                    "initial": "F.A.",
                    "last": "Ennis"
                },
                {
                    "first": "Sharone",
                    "initial": "S.",
                    "last": "Green"
                },
                {
                    "first": "Philip",
                    "initial": "P.",
                    "last": "Bedford"
                }
            ],
            "doi": "10.1073/pnas.0601932103",
            "firstpage": "6694",
            "issn": "00278424",
            "lastpage": "6699",
            "pmid": "16617103",
            "pub_year": 2006,
            "title": "A live, attenuated recombinant West Nile virus vaccine",
            "volume": "103"
        },
        "b0060": {
            "authors": [
                {
                    "first": "Rex",
                    "initial": "R.",
                    "last": "Biedenbender"
                },
                {
                    "first": "Joan",
                    "initial": "J.",
                    "last": "Bevilacqua"
                },
                {
                    "first": "Anne M.",
                    "initial": "A.M.",
                    "last": "Gregg"
                },
                {
                    "first": "Mike",
                    "initial": "M.",
                    "last": "Watson"
                },
                {
                    "first": "Gustavo",
                    "initial": "G.",
                    "last": "Dayan"
                }
            ],
            "doi": "10.1093/infdis/jiq003",
            "firstpage": "75",
            "issn": "00221899",
            "lastpage": "84",
            "pmid": "21148499",
            "pub_year": 2011,
            "title": "Phase II, randomized, double-blind, placebo-controlled, multicenter study to investigate the immunogenicity and safety of a West Nile virus vaccine in healthy adults",
            "volume": "203"
        },
        "b0065": {
            "authors": [
                {
                    "first": "Gustavo H.",
                    "initial": "G.H.",
                    "last": "Dayan"
                },
                {
                    "first": "Joan",
                    "initial": "J.",
                    "last": "Bevilacqua"
                },
                {
                    "first": "Dorothy",
                    "initial": "D.",
                    "last": "Coleman"
                },
                {
                    "first": "Aileen",
                    "initial": "A.",
                    "last": "Buldo"
                },
                {
                    "first": "George",
                    "initial": "G.",
                    "last": "Risi"
                }
            ],
            "doi": "10.1016/j.vaccine.2012.08.063",
            "firstpage": "6656",
            "issn": "0264410X",
            "lastpage": "6664",
            "pmid": "22959989",
            "pub_year": 2012,
            "title": "Phase II, dose ranging study of the safety and immunogenicity of single dose West Nile vaccine in healthy adults \u226550 years of age",
            "volume": "30"
        },
        "b0070": {
            "authors": [
                {
                    "first": "Douglas G.",
                    "initial": "D.G.",
                    "last": "Widman"
                },
                {
                    "first": "Tomohiro",
                    "initial": "T.",
                    "last": "Ishikawa"
                },
                {
                    "first": "Luis D.",
                    "initial": "L.D.",
                    "last": "Giavedoni"
                },
                {
                    "first": "Vida L.",
                    "initial": "V.L.",
                    "last": "Hodara"
                },
                {
                    "first": "Melissa",
                    "initial": "M.",
                    "last": "De La Garza"
                },
                {
                    "first": "Jessica A.",
                    "initial": "J.A.",
                    "last": "Montalbo"
                },
                {
                    "first": "Amelia P.",
                    "initial": "A.P.",
                    "last": "Travassos Da Rosa"
                },
                {
                    "first": "Robert B.",
                    "initial": "R.B.",
                    "last": "Tesh"
                },
                {
                    "first": "Jean L.",
                    "initial": "J.L.",
                    "last": "Patterson"
                },
                {
                    "first": "Ricardo",
                    "initial": "R.",
                    "last": "Carrion"
                },
                {
                    "first": "Nigel",
                    "initial": "N.",
                    "last": "Bourne"
                },
                {
                    "first": "Peter W.",
                    "initial": "P.W.",
                    "last": "Mason"
                }
            ],
            "doi": "10.4269/ajtmh.2010.09-0310",
            "firstpage": "1160",
            "issn": "00029637",
            "lastpage": "1167",
            "pmid": "20519618",
            "pub_year": 2010,
            "title": "Evaluation of RepliVAX WN, a single-cycle flavivirus vaccine, in a non-human primate model of west nile virus infection",
            "volume": "82"
        },
        "b0075": {
            "authors": [
                {
                    "first": "Melissa C.",
                    "initial": "M.C.",
                    "last": "Whiteman"
                },
                {
                    "first": "Li",
                    "initial": "L.",
                    "last": "Li"
                },
                {
                    "first": "Jason A.",
                    "initial": "J.A.",
                    "last": "Wicker"
                },
                {
                    "first": "Richard M.",
                    "initial": "R.M.",
                    "last": "Kinney"
                },
                {
                    "first": "Claire",
                    "initial": "C.",
                    "last": "Huang"
                },
                {
                    "first": "David W.C.",
                    "initial": "D.W.C.",
                    "last": "Beasley"
                },
                {
                    "first": "Kyung Min",
                    "initial": "K.M.",
                    "last": "Chung"
                },
                {
                    "first": "Michael S.",
                    "initial": "M.S.",
                    "last": "Diamond"
                },
                {
                    "first": "Tom",
                    "initial": "T.",
                    "last": "Solomon"
                },
                {
                    "first": "Alan D.T.",
                    "initial": "A.D.T.",
                    "last": "Barrett"
                }
            ],
            "doi": "10.1016/j.vaccine.2009.10.112",
            "firstpage": "1075",
            "issn": "0264410X",
            "lastpage": "1083",
            "pmid": "19896447",
            "pub_year": 2010,
            "title": "Development and characterization of non-glycosylated E and NS1 mutant viruses as a potential candidate vaccine for West Nile virus",
            "volume": "28"
        },
        "b0080": {
            "authors": [
                {
                    "first": "Douglas G.",
                    "initial": "D.G.",
                    "last": "Widman"
                },
                {
                    "first": "Tomohiro",
                    "initial": "T.",
                    "last": "Ishikawa"
                },
                {
                    "first": "Rafik",
                    "initial": "R.",
                    "last": "Fayzulin"
                },
                {
                    "first": "Nigel",
                    "initial": "N.",
                    "last": "Bourne"
                },
                {
                    "first": "Peter W.",
                    "initial": "P.W.",
                    "last": "Mason"
                }
            ],
            "doi": "10.1016/j.vaccine.2008.03.009",
            "firstpage": "2762",
            "issn": "0264410X",
            "lastpage": "2771",
            "pmid": "18423946",
            "pub_year": 2008,
            "title": "Construction and characterization of a second-generation pseudoinfectious West Nile virus vaccine propagated using a new cultivation system",
            "volume": "26"
        },
        "b0085": {
            "authors": [
                {
                    "first": "Julie E.",
                    "initial": "J.E.",
                    "last": "Ledgerwood"
                },
                {
                    "first": "Theodore C.",
                    "initial": "T.C.",
                    "last": "Pierson"
                },
                {
                    "first": "Sarah A.",
                    "initial": "S.A.",
                    "last": "Hubka"
                },
                {
                    "first": "Niraj",
                    "initial": "N.",
                    "last": "Desai"
                },
                {
                    "first": "Steve",
                    "initial": "S.",
                    "last": "Rucker"
                },
                {
                    "first": "Ingelise J.",
                    "initial": "I.J.",
                    "last": "Gordon"
                },
                {
                    "first": "Mary E.",
                    "initial": "M.E.",
                    "last": "Enama"
                },
                {
                    "first": "Steevenson",
                    "initial": "S.",
                    "last": "Nelson"
                },
                {
                    "first": "Martha",
                    "initial": "M.",
                    "last": "Nason"
                },
                {
                    "first": "Wenjuan",
                    "initial": "W.",
                    "last": "Gu"
                },
                {
                    "first": "Nikkida",
                    "initial": "N.",
                    "last": "Bundrant"
                },
                {
                    "first": "Richard A.",
                    "initial": "R.A.",
                    "last": "Koup"
                },
                {
                    "first": "Robert T.",
                    "initial": "R.T.",
                    "last": "Bailer"
                },
                {
                    "first": "John R.",
                    "initial": "J.R.",
                    "last": "Mascola"
                },
                {
                    "first": "Gary J.",
                    "initial": "G.J.",
                    "last": "Nabel"
                },
                {
                    "first": "Barney S.",
                    "initial": "B.S.",
                    "last": "Graham"
                }
            ],
            "doi": "10.1093/infdis/jir054",
            "firstpage": "1396",
            "issn": "00221899",
            "lastpage": "1404",
            "pmid": "21398392",
            "pub_year": 2011,
            "title": "A west nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial",
            "volume": "203"
        },
        "b0090": {
            "authors": [
                {
                    "first": "Steevenson",
                    "initial": "S.",
                    "last": "Nelson"
                },
                {
                    "first": "Christiane A.",
                    "initial": "C.A.",
                    "last": "Jost"
                },
                {
                    "first": "Qinq",
                    "initial": "Q.",
                    "last": "Xu"
                },
                {
                    "first": "Jessica",
                    "initial": "J.",
                    "last": "Ess"
                },
                {
                    "first": "Julie E.",
                    "initial": "J.E.",
                    "last": "Martin"
                },
                {
                    "first": "Theodore",
                    "initial": "T.",
                    "last": "Oliphant"
                },
                {
                    "first": "Stephen S.",
                    "initial": "S.S.",
                    "last": "Whitehead"
                },
                {
                    "first": "Anna P.",
                    "initial": "A.P.",
                    "last": "Durbin"
                },
                {
                    "first": "Barney S.",
                    "initial": "B.S.",
                    "last": "Graham"
                },
                {
                    "first": "Michael S.",
                    "initial": "M.S.",
                    "last": "Diamond"
                },
                {
                    "first": "Theodore C.",
                    "initial": "T.C.",
                    "last": "Pierson"
                }
            ],
            "doi": "10.1371/journal.ppat.1000060",
            "issn": "15537366",
            "pmid": "18464894",
            "pub_year": 2008,
            "title": "Maturation of West Nile virus modulates sensitivity to antibody-mediated neutralization",
            "volume": "4"
        },
        "b0095": {
            "authors": [
                {
                    "first": "Julie E.",
                    "initial": "J.E.",
                    "last": "Martin"
                },
                {
                    "first": "Theodore C.",
                    "initial": "T.C.",
                    "last": "Pierson"
                },
                {
                    "first": "Sarah",
                    "initial": "S.",
                    "last": "Hubka"
                },
                {
                    "first": "Steve",
                    "initial": "S.",
                    "last": "Rucker"
                },
                {
                    "first": "Ingelise J.",
                    "initial": "I.J.",
                    "last": "Gordon"
                },
                {
                    "first": "Mary E.",
                    "initial": "M.E.",
                    "last": "Enama"
                },
                {
                    "first": "Charla A.",
                    "initial": "C.A.",
                    "last": "Andrews"
                },
                {
                    "first": "Qing",
                    "initial": "Q.",
                    "last": "Xu"
                },
                {
                    "first": "Brent S.",
                    "initial": "B.S.",
                    "last": "Davis"
                },
                {
                    "first": "Martha C.",
                    "initial": "M.C.",
                    "last": "Nason"
                },
                {
                    "first": "Michael P.",
                    "initial": "M.P.",
                    "last": "Fay"
                },
                {
                    "first": "Richard A.",
                    "initial": "R.A.",
                    "last": "Koup"
                },
                {
                    "first": "Mario",
                    "initial": "M.",
                    "last": "Roederer"
                },
                {
                    "first": "Robert T.",
                    "initial": "R.T.",
                    "last": "Bailer"
                },
                {
                    "first": "Phillip L.",
                    "initial": "P.L.",
                    "last": "Gomez"
                },
                {
                    "first": "John R.",
                    "initial": "J.R.",
                    "last": "Mascola"
                },
                {
                    "first": "Gwong Jen J.",
                    "initial": "G.J.J.",
                    "last": "Chang"
                },
                {
                    "first": "Gary J.",
                    "initial": "G.J.",
                    "last": "Nabel"
                },
                {
                    "first": "Barney S.",
                    "initial": "B.S.",
                    "last": "Graham"
                }
            ],
            "doi": "10.1086/523650",
            "firstpage": "1732",
            "issn": "00221899",
            "lastpage": "1740",
            "pmid": "18190252",
            "pub_year": 2007,
            "title": "A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial",
            "volume": "196"
        },
        "b0100": {
            "authors": [
                {
                    "first": "Michael M.",
                    "initial": "M.M.",
                    "last": "Lieberman"
                },
                {
                    "first": "Vivek R.",
                    "initial": "V.R.",
                    "last": "Nerurkar"
                },
                {
                    "first": "Haiyan",
                    "initial": "H.",
                    "last": "Luo"
                },
                {
                    "first": "Bruce",
                    "initial": "B.",
                    "last": "Cropp"
                },
                {
                    "first": "Ricardo",
                    "initial": "R.",
                    "last": "Carrion"
                },
                {
                    "first": "Melissa",
                    "initial": "M.",
                    "last": "De La Garza"
                },
                {
                    "first": "Beth Ann",
                    "initial": "B.A.",
                    "last": "Coller"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Clements"
                },
                {
                    "first": "Steven",
                    "initial": "S.",
                    "last": "Ogata"
                },
                {
                    "first": "Teri",
                    "initial": "T.",
                    "last": "Wong"
                },
                {
                    "first": "Tim",
                    "initial": "T.",
                    "last": "Martyak"
                },
                {
                    "first": "Carolyn",
                    "initial": "C.",
                    "last": "Weeks-Levy"
                }
            ],
            "doi": "10.1128/CVI.00119-09",
            "firstpage": "1332",
            "issn": "15566811",
            "lastpage": "1337",
            "pmid": "19641099",
            "pub_year": 2009,
            "title": "Immunogenicity and protective efficacy of a recombinant subunit West Nile Virus vaccine in rhesus monkeys",
            "volume": "16"
        },
        "b0105": {
            "authors": [
                {
                    "first": "Klaus K.",
                    "initial": "K.K.",
                    "last": "Orlinger"
                },
                {
                    "first": "Georg W.",
                    "initial": "G.W.",
                    "last": "Holzer"
                },
                {
                    "first": "Julia",
                    "initial": "J.",
                    "last": "Schwaiger"
                },
                {
                    "first": "Josef",
                    "initial": "J.",
                    "last": "Mayrhofer"
                },
                {
                    "first": "Karl",
                    "initial": "K.",
                    "last": "Schmid"
                },
                {
                    "first": "Otfried",
                    "initial": "O.",
                    "last": "Kistner"
                },
                {
                    "first": "P.",
                    "initial": "P.",
                    "last": "Noel Barrett"
                },
                {
                    "first": "Falko G.",
                    "initial": "F.G.",
                    "last": "Falkner"
                }
            ],
            "doi": "10.1016/j.vaccine.2010.02.092",
            "firstpage": "3318",
            "issn": "0264410X",
            "lastpage": "3324",
            "pmid": "20211218",
            "pub_year": 2010,
            "title": "An inactivated West Nile Virus vaccine derived from a chemically synthesized cDNA system",
            "volume": "28"
        },
        "b0110": {
            "authors": [
                {
                    "first": "Chang Kweng",
                    "initial": "C.K.",
                    "last": "Lim"
                },
                {
                    "first": "Tomohiko",
                    "initial": "T.",
                    "last": "Takasaki"
                },
                {
                    "first": "Akira",
                    "initial": "A.",
                    "last": "Kotaki"
                },
                {
                    "first": "Ichiro",
                    "initial": "I.",
                    "last": "Kurane"
                }
            ],
            "doi": "10.1016/j.virol.2007.12.021",
            "firstpage": "60",
            "issn": "00426822",
            "lastpage": "70",
            "pmid": "18221765",
            "pub_year": 2008,
            "title": "Vero cell-derived inactivated West Nile (WN) vaccine induces protective immunity against lethal WN virus infection in mice and shows a facilitated neutralizing antibody response in mice previously immunized with Japanese encephalitis vaccine",
            "volume": "374"
        },
        "b0115": null,
        "b0120": {
            "authors": [
                {
                    "first": "Michael S.",
                    "initial": "M.S.",
                    "last": "Diamond"
                },
                {
                    "first": "Theodore C.",
                    "initial": "T.C.",
                    "last": "Pierson"
                },
                {
                    "first": "Daved H.",
                    "initial": "D.H.",
                    "last": "Fremont"
                }
            ],
            "doi": "10.1111/j.1600-065X.2008.00676.x",
            "firstpage": "212",
            "issn": "01052896",
            "lastpage": "225",
            "pmid": "18837784",
            "pub_year": 2008,
            "title": "The structural immunology of antibody protection against West Nile virus",
            "volume": "225"
        },
        "b0125": {
            "authors": [
                {
                    "first": "Ian J.",
                    "initial": "I.J.",
                    "last": "Amanna"
                },
                {
                    "first": "Hans Peter",
                    "initial": "H.P.",
                    "last": "Rau\u00e9"
                },
                {
                    "first": "Mark K.",
                    "initial": "M.K.",
                    "last": "Slifka"
                }
            ],
            "doi": "10.1038/nm.2763",
            "firstpage": "974",
            "issn": "10788956",
            "lastpage": "979",
            "pmid": "22635006",
            "pub_year": 2012,
            "title": "Development of a new hydrogen peroxide-based vaccine platform",
            "volume": "18"
        },
        "b0130": {
            "authors": [
                {
                    "first": "Amelia K.",
                    "initial": "A.K.",
                    "last": "Pinto"
                },
                {
                    "first": "Justin M.",
                    "initial": "J.M.",
                    "last": "Richner"
                },
                {
                    "first": "Elizabeth A.",
                    "initial": "E.A.",
                    "last": "Poore"
                },
                {
                    "first": "Pradnya P.",
                    "initial": "P.P.",
                    "last": "Patil"
                },
                {
                    "first": "Ian J.",
                    "initial": "I.J.",
                    "last": "Amanna"
                },
                {
                    "first": "Mark K.",
                    "initial": "M.K.",
                    "last": "Slifka"
                },
                {
                    "first": "Michael S.",
                    "initial": "M.S.",
                    "last": "Diamond"
                }
            ],
            "doi": "10.1128/JVI.02903-12",
            "firstpage": "1926",
            "issn": "0022538X",
            "lastpage": "1936",
            "pmid": "23221549",
            "pub_year": 2013,
            "title": "A hydrogen peroxide-inactivated virus vaccine elicits humoral and cellular immunity and protects against lethal west nile virus infection in aged mice",
            "volume": "87"
        },
        "b0135": {
            "authors": [
                {
                    "first": "Elizabeth A.",
                    "initial": "E.A.",
                    "last": "Poore"
                },
                {
                    "first": "Dawn K.",
                    "initial": "D.K.",
                    "last": "Slifka"
                },
                {
                    "first": "Hans Peter",
                    "initial": "H.P.",
                    "last": "Rau\u00e9"
                },
                {
                    "first": "Archana",
                    "initial": "A.",
                    "last": "Thomas"
                },
                {
                    "first": "Erika",
                    "initial": "E.",
                    "last": "Hammarlund"
                },
                {
                    "first": "Benjamin K.",
                    "initial": "B.K.",
                    "last": "Quintel"
                },
                {
                    "first": "Lindsay L.",
                    "initial": "L.L.",
                    "last": "Torrey"
                },
                {
                    "first": "Ariel M.",
                    "initial": "A.M.",
                    "last": "Slifka"
                },
                {
                    "first": "Justin M.",
                    "initial": "J.M.",
                    "last": "Richner"
                },
                {
                    "first": "Melissa E.",
                    "initial": "M.E.",
                    "last": "Dubois"
                },
                {
                    "first": "Lawrence P.",
                    "initial": "L.P.",
                    "last": "Johnson"
                },
                {
                    "first": "Michael S.",
                    "initial": "M.S.",
                    "last": "Diamond"
                },
                {
                    "first": "Mark K.",
                    "initial": "M.K.",
                    "last": "Slifka"
                },
                {
                    "first": "Ian J.",
                    "initial": "I.J.",
                    "last": "Amanna"
                }
            ],
            "doi": "10.1016/j.vaccine.2016.11.080",
            "firstpage": "283",
            "issn": "0264410X",
            "lastpage": "292",
            "pmid": "27919629",
            "pub_year": 2017,
            "title": "Pre-clinical development of a hydrogen peroxide-inactivated West Nile virus vaccine",
            "volume": "35"
        },
        "b0140": {
            "authors": [
                {
                    "first": "Thomas P.",
                    "initial": "T.P.",
                    "last": "Monath"
                },
                {
                    "first": "Cynthia K.",
                    "initial": "C.K.",
                    "last": "Lee"
                },
                {
                    "first": "Justin G.",
                    "initial": "J.G.",
                    "last": "Julander"
                },
                {
                    "first": "Alicja",
                    "initial": "A.",
                    "last": "Brown"
                },
                {
                    "first": "David W.",
                    "initial": "D.W.",
                    "last": "Beasley"
                },
                {
                    "first": "Douglas M.",
                    "initial": "D.M.",
                    "last": "Watts"
                },
                {
                    "first": "Edward",
                    "initial": "E.",
                    "last": "Hayman"
                },
                {
                    "first": "Patrick",
                    "initial": "P.",
                    "last": "Guertin"
                },
                {
                    "first": "Joseph",
                    "initial": "J.",
                    "last": "Makowiecki"
                },
                {
                    "first": "Joseph",
                    "initial": "J.",
                    "last": "Crowell"
                },
                {
                    "first": "Philip",
                    "initial": "P.",
                    "last": "Levesque"
                },
                {
                    "first": "Gavin C.",
                    "initial": "G.C.",
                    "last": "Bowick"
                },
                {
                    "first": "Merribeth",
                    "initial": "M.",
                    "last": "Morin"
                },
                {
                    "first": "Elizabeth",
                    "initial": "E.",
                    "last": "Fowler"
                },
                {
                    "first": "Dennis W.",
                    "initial": "D.W.",
                    "last": "Trent"
                }
            ],
            "doi": "10.1016/j.vaccine.2010.03.023",
            "firstpage": "3827",
            "issn": "0264410X",
            "lastpage": "3840",
            "pmid": "20347059",
            "pub_year": 2010,
            "title": "Inactivated yellow fever 17D vaccine: Development and nonclinical safety, immunogenicity and protective activity",
            "volume": "28"
        },
        "b0145": {
            "authors": [
                {
                    "first": "Katrin",
                    "initial": "K.",
                    "last": "Dubischar-Kastner"
                },
                {
                    "first": "Susanne",
                    "initial": "S.",
                    "last": "Eder"
                },
                {
                    "first": "Vera",
                    "initial": "V.",
                    "last": "Buerger"
                },
                {
                    "first": "Gabriele",
                    "initial": "G.",
                    "last": "Gartner-Woelfl"
                },
                {
                    "first": "Astrid",
                    "initial": "A.",
                    "last": "Kaltenboeck"
                },
                {
                    "first": "Elisabeth",
                    "initial": "E.",
                    "last": "Schuller"
                },
                {
                    "first": "Erich",
                    "initial": "E.",
                    "last": "Tauber"
                },
                {
                    "first": "Christoph",
                    "initial": "C.",
                    "last": "Klade"
                }
            ],
            "doi": "10.1016/j.vaccine.2010.05.069",
            "firstpage": "5197",
            "issn": "0264410X",
            "lastpage": "5202",
            "pmid": "20541581",
            "pub_year": 2010,
            "title": "Long-term immunity and immune response to a booster dose following vaccination with the inactivated Japanese encephalitis vaccine IXIARO\u00ae, IC51",
            "volume": "28"
        },
        "b0150": {
            "authors": [
                {
                    "first": "Arthur",
                    "initial": "A.",
                    "last": "Lyons"
                },
                {
                    "first": "Niranjan",
                    "initial": "N.",
                    "last": "Kanesa-thasan"
                },
                {
                    "first": "Robert A.",
                    "initial": "R.A.",
                    "last": "Kuschner"
                },
                {
                    "first": "Kenneth H.",
                    "initial": "K.H.",
                    "last": "Eckels"
                },
                {
                    "first": "Robert",
                    "initial": "R.",
                    "last": "Putnak"
                },
                {
                    "first": "Wellington",
                    "initial": "W.",
                    "last": "Sun"
                },
                {
                    "first": "Robert",
                    "initial": "R.",
                    "last": "Burge"
                },
                {
                    "first": "Andrew C.",
                    "initial": "A.C.",
                    "last": "Towle"
                },
                {
                    "first": "Paul",
                    "initial": "P.",
                    "last": "Wilson"
                },
                {
                    "first": "Erich",
                    "initial": "E.",
                    "last": "Tauber"
                },
                {
                    "first": "David W.",
                    "initial": "D.W.",
                    "last": "Vaughn"
                }
            ],
            "doi": "10.1016/j.vaccine.2006.12.046",
            "firstpage": "3445",
            "issn": "0264410X",
            "lastpage": "3453",
            "pmid": "17241714",
            "pub_year": 2007,
            "title": "A Phase 2 study of a purified, inactivated virus vaccine to prevent Japanese encephalitis",
            "volume": "25"
        },
        "b0155": {
            "authors": [
                {
                    "first": "Erin",
                    "initial": "E.",
                    "last": "Mehlhop"
                },
                {
                    "first": "Kevin",
                    "initial": "K.",
                    "last": "Whitby"
                },
                {
                    "first": "Theodore",
                    "initial": "T.",
                    "last": "Oliphant"
                },
                {
                    "first": "Anantha",
                    "initial": "A.",
                    "last": "Marri"
                },
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Engle"
                },
                {
                    "first": "Michael S.",
                    "initial": "M.S.",
                    "last": "Diamond"
                }
            ],
            "doi": "10.1128/JVI.79.12.7466-7477.2005",
            "firstpage": "7466",
            "issn": "0022538X",
            "lastpage": "7477",
            "pmid": "15919902",
            "pub_year": 2005,
            "title": "Complement activation is required for induction of a protective antibody response against West Nile virus infection",
            "volume": "79"
        },
        "b0160": {
            "authors": [
                {
                    "first": "Ian J.",
                    "initial": "I.J.",
                    "last": "Amanna"
                },
                {
                    "first": "Nichole E.",
                    "initial": "N.E.",
                    "last": "Carlson"
                },
                {
                    "first": "Mark K.",
                    "initial": "M.K.",
                    "last": "Slifka"
                }
            ],
            "doi": "10.1056/NEJMoa066092",
            "firstpage": "1903",
            "issn": "00284793",
            "lastpage": "1915",
            "pmid": "17989383",
            "pub_year": 2007,
            "title": "Duration of humoral immunity to common viral and vaccine antigens",
            "volume": "357"
        },
        "b0165": {
            "authors": [
                {
                    "first": "Bradford D.",
                    "initial": "B.D.",
                    "last": "Gessner"
                },
                {
                    "first": "Neal",
                    "initial": "N.",
                    "last": "Halsey"
                }
            ],
            "doi": "10.1016/j.vaccine.2017.05.003",
            "firstpage": "3452",
            "issn": "0264410X",
            "lastpage": "3456",
            "pmid": "28528764",
            "pub_year": 2017,
            "title": "Dengue vaccine safety signal: Immune enhancement, waning immunity, or chance occurrence?",
            "volume": "35"
        },
        "b0170": {
            "authors": [
                {
                    "first": "Guillermo",
                    "initial": "G.",
                    "last": "Posadas-Herrera"
                },
                {
                    "first": "Shingo",
                    "initial": "S.",
                    "last": "Inoue"
                },
                {
                    "first": "Isao",
                    "initial": "I.",
                    "last": "Fuke"
                },
                {
                    "first": "Yuko",
                    "initial": "Y.",
                    "last": "Muraki"
                },
                {
                    "first": "Cynthia A.",
                    "initial": "C.A.",
                    "last": "Mapua"
                },
                {
                    "first": "Afjal Hossain",
                    "initial": "A.H.",
                    "last": "Khan"
                },
                {
                    "first": "Maria del Carmen",
                    "initial": "M.d.C.",
                    "last": "Parquet"
                },
                {
                    "first": "Sadao",
                    "initial": "S.",
                    "last": "Manabe"
                },
                {
                    "first": "Osamu",
                    "initial": "O.",
                    "last": "Tanishita"
                },
                {
                    "first": "Toyokazu",
                    "initial": "T.",
                    "last": "Ishikawa"
                },
                {
                    "first": "Filipinas F.",
                    "initial": "F.F.",
                    "last": "Natividad"
                },
                {
                    "first": "Yoshinobu",
                    "initial": "Y.",
                    "last": "Okuno"
                },
                {
                    "first": "Futoshi",
                    "initial": "F.",
                    "last": "Hasebe"
                },
                {
                    "first": "Kouichi",
                    "initial": "K.",
                    "last": "Morita"
                }
            ],
            "doi": "10.1016/j.vaccine.2010.09.076",
            "firstpage": "7939",
            "issn": "0264410X",
            "lastpage": "7946",
            "pmid": "20933564",
            "pub_year": 2010,
            "title": "Development and evaluation of a formalin-inactivated West Nile Virus vaccine (WN-VAX) for a human vaccine candidate",
            "volume": "28"
        },
        "b0175": {
            "authors": [
                {
                    "first": "Yuko",
                    "initial": "Y.",
                    "last": "Muraki"
                },
                {
                    "first": "Takeshi",
                    "initial": "T.",
                    "last": "Fujita"
                },
                {
                    "first": "Masaaki",
                    "initial": "M.",
                    "last": "Matsuura"
                },
                {
                    "first": "Isao",
                    "initial": "I.",
                    "last": "Fuke"
                },
                {
                    "first": "Sadao",
                    "initial": "S.",
                    "last": "Manabe"
                },
                {
                    "first": "Toyokazu",
                    "initial": "T.",
                    "last": "Ishikawa"
                },
                {
                    "first": "Yoshinobu",
                    "initial": "Y.",
                    "last": "Okuno"
                },
                {
                    "first": "Kouichi",
                    "initial": "K.",
                    "last": "Morita"
                }
            ],
            "doi": "10.1186/s12985-015-0282-8",
            "issn": "1743422X",
            "pmid": "25889682",
            "pub_year": 2015,
            "title": "The efficacy of inactivated West Nile vaccine (WN-VAX) in mice and monkeys",
            "volume": "12"
        },
        "b0180": {
            "authors": [
                {
                    "first": "P. Noel",
                    "initial": "P.N.",
                    "last": "Barrett"
                },
                {
                    "first": "Sara J.",
                    "initial": "S.J.",
                    "last": "Terpening"
                },
                {
                    "first": "Doris",
                    "initial": "D.",
                    "last": "Snow"
                },
                {
                    "first": "Ronald R.",
                    "initial": "R.R.",
                    "last": "Cobb"
                },
                {
                    "first": "Otfried",
                    "initial": "O.",
                    "last": "Kistner"
                }
            ],
            "doi": "10.1080/14760584.2017.1357471",
            "firstpage": "883",
            "issn": "14760584",
            "lastpage": "894",
            "pmid": "28724343",
            "pub_year": 2017,
            "title": "Vero cell technology for rapid development of inactivated whole virus vaccines for emerging viral diseases",
            "volume": "16"
        },
        "b0185": {
            "authors": [
                {
                    "first": "Benjamin K.",
                    "initial": "B.K.",
                    "last": "Quintel"
                },
                {
                    "first": "Archana",
                    "initial": "A.",
                    "last": "Thomas"
                },
                {
                    "first": "Danae E.",
                    "initial": "D.E.",
                    "last": "Poer DeRaad"
                },
                {
                    "first": "Mark K.",
                    "initial": "M.K.",
                    "last": "Slifka"
                },
                {
                    "first": "Ian J.",
                    "initial": "I.J.",
                    "last": "Amanna"
                }
            ],
            "doi": "10.1016/j.vaccine.2018.12.020",
            "firstpage": "4214",
            "issn": "0264410X",
            "lastpage": "4221",
            "pmid": "30606462",
            "pub_year": 2019,
            "title": "Advanced oxidation technology for the development of a next-generation inactivated West Nile virus vaccine",
            "volume": "37"
        }
    },
    "body_text": [
        {
            "endOffset": 27128,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0070",
                    "title": "Statistical analysis"
                }
            ],
            "secId": "s0075",
            "sentence": "Vaccine dose groups were compared for baseline characteristics including demographics and laboratory measurements using descriptive statistics.",
            "startOffset": 26985,
            "title": "Safety"
        },
        {
            "endOffset": 16678,
            "parents": [],
            "secId": "s0005",
            "sentence": "Based on pre-clinical data described above and studies of other inactivated alum-adsorbed flavivirus vaccines, the antigen doses evaluated were 1 mcg and 4 mcg.",
            "startOffset": 16518,
            "title": "Introduction"
        },
        {
            "endOffset": 37403,
            "parents": [
                {
                    "id": "s0085",
                    "title": "Results"
                },
                {
                    "id": "s0120",
                    "title": "Immunogenicity results"
                }
            ],
            "secId": "s0125",
            "sentence": "At the 4 mcg dose, Hydrovax-001 did not induce neutralizing antibody titers following a single dose, but reached 31% seroconversion within 15 days after a second dose of vaccine in the PP population with antibody responses waning at days 180 and 365 post Dose 2 (Table 2).",
            "startOffset": 37131,
            "title": "PRNT50 and complement-enhanced PRNT50 seroresponses"
        },
        {
            "endOffset": 31685,
            "parents": [
                {
                    "id": "s0085",
                    "title": "Results"
                },
                {
                    "id": "s0095",
                    "title": "Safety"
                }
            ],
            "secId": "s0100",
            "sentence": "There were no Grade 3 (Severe) systemic events reported after either vaccination.",
            "startOffset": 31604,
            "title": "Solicited events"
        },
        {
            "endOffset": 28127,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0070",
                    "title": "Statistical analysis"
                }
            ],
            "secId": "s0080",
            "sentence": "Rates of seroconversion for PRNT50 titer, complement-enhanced PRNT50 titer, and ELISA titer were summarized by tabulating the frequency of positive responses by treatment group at day 29 after first vaccination, day 57 after second vaccination in addition to other serologic time points.",
            "startOffset": 27840,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 25137,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0035",
                    "title": "Data collection"
                },
                {
                    "id": "s0055",
                    "title": "Immunogenicity"
                }
            ],
            "refoffsets": {
                "b0125": {
                    "endOffset": 25136,
                    "startOffset": 25132
                }
            },
            "secId": "s0065",
            "sentence": "For the ELISA analyses, this assay is performed by testing serial dilutions of serum for reactivity against WNV in an ELISA format as previously described [25].",
            "startOffset": 24977,
            "title": "ELISA"
        },
        {
            "endOffset": 43945,
            "parents": [],
            "secId": "s0135",
            "sentence": "The use of highly pathogenic strains of virus for inactivated vaccines creates logistical issues associated with the handling of BSL3 pathogens during large-scale cGMP manufacturing, in addition to safety concerns if complete inactivation is not achieved.",
            "startOffset": 43690,
            "title": "Discussion"
        },
        {
            "endOffset": 19646,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "An unblinded site research pharmacist prepared the study product and an unblinded research nurse performed an IM injection of the study product into the deltoid per the randomization assignment.",
            "startOffset": 19452,
            "title": "Vaccine administration and masking"
        },
        {
            "endOffset": 42566,
            "parents": [],
            "refoffsets": {
                "b0050": {
                    "endOffset": 42565,
                    "startOffset": 42561
                }
            },
            "secId": "s0135",
            "sentence": "The rWN/DEN4\u039430 vaccine demonstrated primary seroconversion rates of 55\u201375% depending on the vaccine dosage and geometric mean neutralizing antibody titers that peaked between 28 and 42 days after vaccination before declining to PRNT60 = 15\u201376 by 180 days after vaccination [10].",
            "startOffset": 42287,
            "title": "Discussion"
        },
        {
            "endOffset": 25257,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0035",
                    "title": "Data collection"
                },
                {
                    "id": "s0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0065",
            "sentence": "The values reported represent the reciprocal of the last serum dilution in which a sample scored positive in the assay.",
            "startOffset": 25138,
            "title": "ELISA"
        },
        {
            "endOffset": 46175,
            "parents": [],
            "secId": "s0135",
            "sentence": "If a similar improvement in immunogenicity is observed in human subjects, then it is possible that higher and potentially more durable antibody responses may be attained.",
            "startOffset": 46005,
            "title": "Discussion"
        },
        {
            "endOffset": 17111,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Included subjects were required to be seronegative to West Nile virus.",
            "startOffset": 17041,
            "title": "Design and conduct of the clinical trial"
        },
        {
            "endOffset": 17040,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The study was conducted at Duke University after review and approval by the Duke University Health System Institutional Review Board.",
            "startOffset": 16907,
            "title": "Design and conduct of the clinical trial"
        },
        {
            "endOffset": 22537,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0035",
                    "title": "Data collection"
                }
            ],
            "secId": "s0045",
            "sentence": "Safety laboratory evaluations included hematology tests (hemoglobin, white blood cell count and platelet count) and blood chemistry tests (creatinine, blood urea nitrogen, glucose, potassium, alanine aminotransferase, aspartate aminotransferase, and total bilirubin).",
            "startOffset": 22270,
            "title": "Laboratory safety data"
        },
        {
            "endOffset": 41600,
            "parents": [],
            "secId": "s0135",
            "sentence": "At the 1 mcg dose, HydroVax-001 induced a seroresponse in 18% of PP subjects at day 15 following a first dose with up to 41% responding by day 15 following a second dose.",
            "startOffset": 41430,
            "title": "Discussion"
        },
        {
            "endOffset": 37827,
            "parents": [
                {
                    "id": "s0085",
                    "title": "Results"
                },
                {
                    "id": "s0120",
                    "title": "Immunogenicity results"
                }
            ],
            "secId": "s0125",
            "sentence": "For the 1 mcg dose of Hydrovax-001, neutralizing antibody responses were below the limit of detection (Table 3) and seroconversion was not observed among any placebo recipients (data not shown).",
            "startOffset": 37633,
            "title": "PRNT50 and complement-enhanced PRNT50 seroresponses"
        },
        {
            "endOffset": 24096,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0035",
                    "title": "Data collection"
                },
                {
                    "id": "s0055",
                    "title": "Immunogenicity"
                }
            ],
            "refoffsets": {
                "b0130": {
                    "endOffset": 24095,
                    "startOffset": 24088
                },
                "b0135": {
                    "endOffset": 24095,
                    "startOffset": 24088
                }
            },
            "secId": "s0060",
            "sentence": "PRNT50 assays were conducted as previously described [26,27].",
            "startOffset": 24035,
            "title": "Plaque-reduction neutralization titer assay"
        },
        {
            "endOffset": 41429,
            "parents": [],
            "secId": "s0135",
            "sentence": "Exploratory immunogenicity results assessed by ELISA were more robust than those as assessed by PRNT50 and the complement-enhanced PRNT50 assays.",
            "startOffset": 41284,
            "title": "Discussion"
        },
        {
            "endOffset": 19451,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "However, within dose groups, subjects, investigators, and study staff other than unblinded site research pharmacists and unblinded research nurse vaccinators were blinded as to the subject's treatment assignment (vaccine vs. placebo).",
            "startOffset": 19217,
            "title": "Vaccine administration and masking"
        },
        {
            "endOffset": 28260,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0070",
                    "title": "Statistical analysis"
                }
            ],
            "secId": "s0080",
            "sentence": "Response rates for each treatment group are presented with their corresponding 95% confidence interval estimates at each time point.",
            "startOffset": 28128,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 37565,
            "parents": [
                {
                    "id": "s0085",
                    "title": "Results"
                },
                {
                    "id": "s0120",
                    "title": "Immunogenicity results"
                }
            ],
            "secId": "s0125",
            "sentence": "Results in the modified ITT analysis were similar with a slightly lower seroconversion rate of 28% reported at days 15 and 29 post Dose 2 (Supplemental Table 5).",
            "startOffset": 37404,
            "title": "PRNT50 and complement-enhanced PRNT50 seroresponses"
        },
        {
            "endOffset": 22269,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0035",
                    "title": "Data collection"
                }
            ],
            "secId": "s0045",
            "sentence": "Blood samples for safety laboratory assessments were collected at screening, at second vaccination, and at 4 and 15 days following each vaccination.",
            "startOffset": 22121,
            "title": "Laboratory safety data"
        },
        {
            "endOffset": 18213,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0135": {
                    "endOffset": 18212,
                    "startOffset": 18208
                }
            },
            "secId": "s0020",
            "sentence": "HydroVax-001 drug product contains 4 mcg purified whole virion WNV formulated in a volume of 0.5 mL/dose with 0.1% aluminum hydroxide and 2% sorbitol in phosphate-buffered saline [27].",
            "startOffset": 18029,
            "title": "Study product"
        },
        {
            "endOffset": 25909,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0035",
                    "title": "Data collection"
                },
                {
                    "id": "s0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0065",
            "sentence": "Alternatively, for subjects with a baseline ELISA value >200, the subject needed to demonstrate a four-fold rise at follow-up for seroconversion.",
            "startOffset": 25764,
            "title": "ELISA"
        },
        {
            "endOffset": 36357,
            "parents": [
                {
                    "id": "s0085",
                    "title": "Results"
                },
                {
                    "id": "s0095",
                    "title": "Safety"
                }
            ],
            "secId": "s0115",
            "sentence": "Blood samples were obtained on day 4 after each vaccination with HydroVax-001 or placebo for WNV viremia testing using a standard plaque assay.",
            "startOffset": 36214,
            "title": "Viremia"
        },
        {
            "endOffset": 42717,
            "parents": [],
            "secId": "s0135",
            "sentence": "Booster vaccination at day 180 increased seroconversion rates to 89%, although geometric mean PRNT60 levels reached a peak of only 57 (range, 17\u2013134).",
            "startOffset": 42567,
            "title": "Discussion"
        },
        {
            "endOffset": 27465,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0070",
                    "title": "Statistical analysis"
                }
            ],
            "secId": "s0075",
            "sentence": "Solicited AEs and laboratory toxicities were analyzed by taking the most severe response over the follow-up period, dichotomizing into a binary variable (none versus mild, moderate, or severe) and using exact confidence intervals to summarize the reactogenicity and toxicity rates.",
            "startOffset": 27184,
            "title": "Safety"
        },
        {
            "endOffset": 17605,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "In each group, 20 subjects received vaccine and a total of 10 subjects received placebo.",
            "startOffset": 17517,
            "title": "Design and conduct of the clinical trial"
        },
        {
            "endOffset": 26076,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0070",
            "sentence": "This study was exploratory, designed to estimate event rates and patterns of immune responses rather than to test formal statistical hypotheses.",
            "startOffset": 25932,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 31419,
            "parents": [
                {
                    "id": "s0085",
                    "title": "Results"
                },
                {
                    "id": "s0095",
                    "title": "Safety"
                }
            ],
            "secId": "s0100",
            "sentence": "Reported rates of headache were similar with 30% (6 subjects) in the 1 mcg group, 20% (4 subjects) in the 4 mcg group, and 50% (5 subjects) in the placebo group.",
            "startOffset": 31258,
            "title": "Solicited events"
        },
        {
            "endOffset": 37130,
            "parents": [
                {
                    "id": "s0085",
                    "title": "Results"
                },
                {
                    "id": "s0120",
                    "title": "Immunogenicity results"
                }
            ],
            "secId": "s0125",
            "sentence": "As expected, none of the participants in the placebo group seroconverted to WNV during the course of the study (data not shown).",
            "startOffset": 37002,
            "title": "PRNT50 and complement-enhanced PRNT50 seroresponses"
        },
        {
            "endOffset": 14699,
            "parents": [],
            "secId": "s0005",
            "sentence": "At present, there is no human vaccine available for WNV infection.",
            "startOffset": 14633,
            "title": "Introduction"
        },
        {
            "endOffset": 29309,
            "parents": [
                {
                    "id": "s0085",
                    "title": "Results"
                }
            ],
            "secId": "s0090",
            "sentence": "Of the total of 51 subjects enrolled, 50 (98%) received the first vaccination, and 43 (84%) received the second vaccination with HydroVax-001 or placebo.",
            "startOffset": 29156,
            "title": "Study participants"
        },
        {
            "endOffset": 26474,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0070",
            "sentence": "The modified intent-to-treat (ITT) population includes all eligible subjects who received at least one dose of study vaccine and contributed both pre- and at least one post-study vaccination blood samples for testing for which valid results were reported.",
            "startOffset": 26219,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 39668,
            "parents": [
                {
                    "id": "s0085",
                    "title": "Results"
                },
                {
                    "id": "s0120",
                    "title": "Immunogenicity results"
                }
            ],
            "secId": "s0130",
            "sentence": "ELISA results for both PP and modified ITT analysis populations were similar (Table 4 and Supplemental Table 7).",
            "startOffset": 39556,
            "title": "ELISA seroresponses"
        },
        {
            "endOffset": 20178,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Laboratory personnel performing antibody assays were blinded to dose group and treatment assignment.",
            "startOffset": 20078,
            "title": "Vaccine administration and masking"
        },
        {
            "endOffset": 14460,
            "parents": [],
            "refoffsets": {
                "b0030": {
                    "endOffset": 14393,
                    "startOffset": 14390
                },
                "b0035": {
                    "endOffset": 14459,
                    "startOffset": 14456
                }
            },
            "secId": "s0005",
            "sentence": "Survivors often experience long-term neurological dysfunction [6] and may be at additional risk of chronic kidney disease (CKD) [7].",
            "startOffset": 14328,
            "title": "Introduction"
        },
        {
            "endOffset": 41186,
            "parents": [],
            "secId": "s0135",
            "sentence": "Overall, the complement-enhanced PRNT50 seroresponses paralleled the PRNT50 responses and at the 4 mcg dose, HydroVax-001 WNV vaccination was more immunogenic by complement-enhanced PRNT50 (50% seroconversion) compared to standard PRNT50 assays (31% seroconversion) among the PP population.",
            "startOffset": 40896,
            "title": "Discussion"
        },
        {
            "endOffset": 21647,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0035",
                    "title": "Data collection"
                }
            ],
            "secId": "s0040",
            "sentence": "Serious AEs (SAEs) were documented from Study Visit 01 (day 1) through Study Visit 10 (day 365 post second vaccination).",
            "startOffset": 21527,
            "title": "Safety"
        },
        {
            "endOffset": 15641,
            "parents": [],
            "refoffsets": {
                "b0135": {
                    "endOffset": 15640,
                    "startOffset": 15636
                }
            },
            "secId": "s0005",
            "sentence": "Preliminary studies explored the use of H2O2-based inactivation of wild-type NY99 WNV for vaccine development, with vaccine antigen able to elicit robust neutralizing antibody responses in amice and protect against lethal challenge [27].",
            "startOffset": 15404,
            "title": "Introduction"
        },
        {
            "endOffset": 23293,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0035",
                    "title": "Data collection"
                }
            ],
            "secId": "s0050",
            "sentence": "Serum samples were aspirated and monolayers overlaid with 3 mL of 0.5% agar in 1X EMEM supplemented with 2.5% FBS, 2 mM l-glutamine and 1\u00d7 penicillin/streptomycin, returned to 37 \u00b0C/5%CO2 and incubated for 2 days.",
            "startOffset": 23080,
            "title": "WNV viremia"
        },
        {
            "endOffset": 20545,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0035",
                    "title": "Data collection"
                }
            ],
            "secId": "s0040",
            "sentence": "Safety outcomes included both solicited and unsolicited adverse events (AEs) experienced by healthy adult volunteers after vaccination with HydroVax-001 vaccine or administration of normal saline placebo.",
            "startOffset": 20341,
            "title": "Safety"
        },
        {
            "endOffset": 27839,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0070",
                    "title": "Statistical analysis"
                }
            ],
            "secId": "s0080",
            "sentence": "Immunogenicity analyses were performed using both the modified ITT population and the PP population.",
            "startOffset": 27739,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 23400,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0035",
                    "title": "Data collection"
                }
            ],
            "secId": "s0050",
            "sentence": "Wells were overlaid with 1 mL of 0.015% neutral red in 1% agar, with plaques enumerated the following day.",
            "startOffset": 23294,
            "title": "WNV viremia"
        },
        {
            "endOffset": 23535,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0035",
                    "title": "Data collection"
                }
            ],
            "secId": "s0050",
            "sentence": "Each experiment included a medium-only plate, as well as a virus-only plate with approximately 50 plaque forming units (PFU) per well.",
            "startOffset": 23401,
            "title": "WNV viremia"
        },
        {
            "endOffset": 16248,
            "parents": [],
            "refoffsets": {
                "b0135": {
                    "endOffset": 16247,
                    "startOffset": 16243
                }
            },
            "secId": "s0005",
            "sentence": "A scaled manufacturing approach for production was established and clinical-grade vaccine, termed HydroVax-001 WNV, was produced and found to be stable, safe and immunogenic in three animal species [27].",
            "startOffset": 16045,
            "title": "Introduction"
        },
        {
            "endOffset": 30847,
            "parents": [
                {
                    "id": "s0085",
                    "title": "Results"
                },
                {
                    "id": "s0095",
                    "title": "Safety"
                }
            ],
            "secId": "s0100",
            "sentence": "The breakdown according to treatment group of adverse events by severity for at least one solicited symptom, at least one systemic solicited symptom or at least one local solicited symptom is shown in Fig. 2.",
            "startOffset": 30639,
            "title": "Solicited events"
        },
        {
            "endOffset": 20077,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "The unblinded site research pharmacist and unblinded research nurse were not involved in study-related assessments nor did they have subject contact for data collection following study vaccine administration.",
            "startOffset": 19869,
            "title": "Vaccine administration and masking"
        },
        {
            "endOffset": 34959,
            "parents": [
                {
                    "id": "s0085",
                    "title": "Results"
                },
                {
                    "id": "s0095",
                    "title": "Safety"
                }
            ],
            "secId": "s0110",
            "sentence": "Overall, seven subjects (14%) experienced abnormal hematology results considered related to study product including 2 subjects (10%) among the 1 mcg group, 4 in the 4 mcg group (20%) and 1 in the placebo group (10%).",
            "startOffset": 34743,
            "title": "Clinical laboratory evaluations"
        },
        {
            "endOffset": 44505,
            "parents": [],
            "refoffsets": {
                "b0180": {
                    "endOffset": 44504,
                    "startOffset": 44500
                }
            },
            "secId": "s0135",
            "sentence": "Similar to our clinical study, other groups using inactivated whole virus vaccines have found it challenging to elicit durable neutralizing antibody responses against WNV [36].",
            "startOffset": 44329,
            "title": "Discussion"
        },
        {
            "endOffset": 36202,
            "parents": [
                {
                    "id": "s0085",
                    "title": "Results"
                },
                {
                    "id": "s0095",
                    "title": "Safety"
                }
            ],
            "secId": "s0110",
            "sentence": "No laboratory abnormalities were associated with symptoms.",
            "startOffset": 36144,
            "title": "Clinical laboratory evaluations"
        },
        {
            "endOffset": 31809,
            "parents": [
                {
                    "id": "s0085",
                    "title": "Results"
                },
                {
                    "id": "s0095",
                    "title": "Safety"
                }
            ],
            "secId": "s0100",
            "sentence": "There were no Grade 2 (Moderate) or 3 (Severe) local events reported after either vaccination with HydroVax-001 or placebo.",
            "startOffset": 31686,
            "title": "Solicited events"
        },
        {
            "endOffset": 24609,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0035",
                    "title": "Data collection"
                },
                {
                    "id": "s0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0060",
            "sentence": "The limit of detection in the neutralizing assay is a titer of <10.",
            "startOffset": 24542,
            "title": "Plaque-reduction neutralization titer assay"
        },
        {
            "endOffset": 31603,
            "parents": [
                {
                    "id": "s0085",
                    "title": "Results"
                },
                {
                    "id": "s0095",
                    "title": "Safety"
                }
            ],
            "secId": "s0100",
            "sentence": "The most commonly reported local symptom was tenderness, including 40% (8 subjects) in the 1 mcg group, 45% (9 subjects) in the 4 mcg group, and 30% (3 subjects) in the placebo group.",
            "startOffset": 31420,
            "title": "Solicited events"
        },
        {
            "endOffset": 35731,
            "parents": [
                {
                    "id": "s0085",
                    "title": "Results"
                },
                {
                    "id": "s0095",
                    "title": "Safety"
                }
            ],
            "secId": "s0110",
            "sentence": "The potassium value was repeated four days later at a supplemental visit and was reported as 5.2 mmol/L (mild).",
            "startOffset": 35620,
            "title": "Clinical laboratory evaluations"
        },
        {
            "endOffset": 45481,
            "parents": [],
            "refoffsets": {
                "b0185": {
                    "endOffset": 45480,
                    "startOffset": 45476
                }
            },
            "secId": "s0135",
            "sentence": "In addition, a recent advance in peroxide-based inactivation technology represents another approach to improving future WNV vaccine design [37].",
            "startOffset": 45337,
            "title": "Discussion"
        },
        {
            "endOffset": 37001,
            "parents": [
                {
                    "id": "s0085",
                    "title": "Results"
                },
                {
                    "id": "s0120",
                    "title": "Immunogenicity results"
                }
            ],
            "secId": "s0125",
            "sentence": "At the 1 mcg dose, Hydrovax-001 did not elicit PRNT50 seroconversion following either the first or the second dose of Hydrovax-001 (Table 2 for PP and Supplemental Table 5 for modified ITT Population).",
            "startOffset": 36800,
            "title": "PRNT50 and complement-enhanced PRNT50 seroresponses"
        },
        {
            "endOffset": 40020,
            "parents": [
                {
                    "id": "s0085",
                    "title": "Results"
                },
                {
                    "id": "s0120",
                    "title": "Immunogenicity results"
                }
            ],
            "secId": "s0130",
            "sentence": "Small increases in ELISA GMTs over baseline were observed in the Hydro-Vax-001 4 mcg group at days 15 and 29 post Dose 1 with further increases noted at days 15, 29 and 57 post Dose 2, with GMTs returning to near baseline at days 180 and 365 following dose two.",
            "startOffset": 39759,
            "title": "ELISA seroresponses"
        },
        {
            "endOffset": 24034,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0035",
                    "title": "Data collection"
                },
                {
                    "id": "s0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0060",
            "sentence": "A complement-enhanced PRNT50 was later included in the study.",
            "startOffset": 23973,
            "title": "Plaque-reduction neutralization titer assay"
        },
        {
            "endOffset": 19118,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0020",
                    "title": "Study product"
                }
            ],
            "refoffsets": {
                "b0135": {
                    "endOffset": 18981,
                    "startOffset": 18977
                }
            },
            "secId": "s0025",
            "sentence": "However, based on further preclinical tests [27], a lower dose of the vaccine test article (4 mcg/0.5 mL) was selected as the \u201chigh dose\u201d, to be compared with a 1 mcg/0.5 mL \u201clow\u201d dose.",
            "startOffset": 18933,
            "title": "Dose rationale"
        },
        {
            "endOffset": 34631,
            "parents": [
                {
                    "id": "s0085",
                    "title": "Results"
                },
                {
                    "id": "s0095",
                    "title": "Safety"
                }
            ],
            "secId": "s0105",
            "sentence": "There were no discernible differences between treatment groups for both all and related unsolicited adverse events.",
            "startOffset": 34516,
            "title": "Unsolicited events"
        },
        {
            "endOffset": 15403,
            "parents": [],
            "refoffsets": {
                "b0125": {
                    "endOffset": 15402,
                    "startOffset": 15395
                },
                "b0130": {
                    "endOffset": 15402,
                    "startOffset": 15395
                },
                "b0135": {
                    "endOffset": 15402,
                    "startOffset": 15395
                }
            },
            "secId": "s0005",
            "sentence": "As an alternative to traditional formaldehyde-based vaccines, a novel hydrogen peroxide (H2O2) inactivation approach has been developed to produce a first-generation whole-virus vaccine against WNV that was tested at concentrations ranging from 1 to 40 mcg/dose [25\u201327].",
            "startOffset": 15133,
            "title": "Introduction"
        },
        {
            "endOffset": 38262,
            "parents": [
                {
                    "id": "s0085",
                    "title": "Results"
                },
                {
                    "id": "s0120",
                    "title": "Immunogenicity results"
                }
            ],
            "secId": "s0125",
            "sentence": "Results from the modified ITT analysis were slightly lower, reaching a peak seroconversion rate of 44% at 15 days following the second dose and declining to 12\u201319% at later time points (Supplemental Table 6).",
            "startOffset": 38054,
            "title": "PRNT50 and complement-enhanced PRNT50 seroresponses"
        },
        {
            "endOffset": 17372,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "For a complete listing of subject inclusion and exclusion criteria refer to ClinicalTrials.gov: NCT02337868.",
            "startOffset": 17264,
            "title": "Design and conduct of the clinical trial"
        },
        {
            "endOffset": 28968,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0070",
                    "title": "Statistical analysis"
                }
            ],
            "secId": "s0080",
            "sentence": "The geometric mean fold rise (GMFR) for each immunogenicity assay and associated exact 95% confidence interval were presented by treatment group at days 15 and 29 after the first vaccination and days 15, 29, 57, 180 and 365 after the second vaccination.",
            "startOffset": 28715,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 13749,
            "parents": [],
            "secId": "s0005",
            "sentence": "West Nile virus (WNV) is a neurotropic flavivirus that cycles between mosquitoes and birds but can also infect humans and other vertebrate animals.",
            "startOffset": 13602,
            "title": "Introduction"
        },
        {
            "endOffset": 41283,
            "parents": [],
            "secId": "s0135",
            "sentence": "In additional exploratory analyses, seroresponses were assessed using a WNV-specific ELISA assay.",
            "startOffset": 41186,
            "title": "Discussion"
        },
        {
            "endOffset": 25407,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0035",
                    "title": "Data collection"
                },
                {
                    "id": "s0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0065",
            "sentence": "All serum dilutions were started at a 1:30 serum dilution.",
            "startOffset": 25349,
            "title": "ELISA"
        },
        {
            "endOffset": 46456,
            "parents": [],
            "secId": "s0135",
            "sentence": "This represents an exciting area for further investigation and may be applicable to not only improved vaccine development against WNV, but may also be suitable for improving vaccines against other clinically important flaviviruses including yellow fever, dengue, and Zika viruses.",
            "startOffset": 46176,
            "title": "Discussion"
        },
        {
            "endOffset": 40698,
            "parents": [],
            "secId": "s0135",
            "sentence": "Seroconversion at the 4 mcg dose reached a peak of 75% among the per-protocol population by WNV-specific ELISA before declining substantially at later time points.",
            "startOffset": 40535,
            "title": "Discussion"
        },
        {
            "endOffset": 31257,
            "parents": [
                {
                    "id": "s0085",
                    "title": "Results"
                },
                {
                    "id": "s0095",
                    "title": "Safety"
                }
            ],
            "secId": "s0100",
            "sentence": "Fatigue was experienced at a rate of 35% (7 subjects) in the 1 mcg group, 30% (6 subjects) in the 4 mcg group, and 40% (4 subjects) in the placebo group.",
            "startOffset": 31104,
            "title": "Solicited events"
        },
        {
            "endOffset": 36434,
            "parents": [
                {
                    "id": "s0085",
                    "title": "Results"
                },
                {
                    "id": "s0095",
                    "title": "Safety"
                }
            ],
            "secId": "s0115",
            "sentence": "There were no positive viremia results for any subject at either time point.",
            "startOffset": 36358,
            "title": "Viremia"
        },
        {
            "endOffset": 30980,
            "parents": [
                {
                    "id": "s0085",
                    "title": "Results"
                },
                {
                    "id": "s0095",
                    "title": "Safety"
                }
            ],
            "secId": "s0100",
            "sentence": "A complete listing of all solicited adverse events following placebo or either vaccine dose can be found in Supplemental Tables 2\u20134.",
            "startOffset": 30848,
            "title": "Solicited events"
        },
        {
            "endOffset": 32904,
            "parents": [
                {
                    "id": "s0085",
                    "title": "Results"
                },
                {
                    "id": "s0095",
                    "title": "Safety"
                }
            ],
            "secId": "s0100",
            "sentence": "There were no reported Grade 2 or Grade 3 systemic events following the second vaccination with HydroVax-001 or placebo.",
            "startOffset": 32784,
            "title": "Solicited events"
        },
        {
            "endOffset": 18441,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "The vaccine and the normal saline placebo/diluent were shipped and stored refrigerated at 2\u20138 \u00b0C.",
            "startOffset": 18344,
            "title": "Study product"
        },
        {
            "endOffset": 38769,
            "parents": [
                {
                    "id": "s0085",
                    "title": "Results"
                },
                {
                    "id": "s0120",
                    "title": "Immunogenicity results"
                }
            ],
            "secId": "s0125",
            "sentence": "Significant increases in GMTs in the HydroVax-001 4 mcg group, as detected by both assays, occurred at days 15 and 29 post Dose 2 but returned close to baseline by day 57 post Dose 2 (Tables 2 and 3).",
            "startOffset": 38569,
            "title": "PRNT50 and complement-enhanced PRNT50 seroresponses"
        },
        {
            "endOffset": 24849,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0035",
                    "title": "Data collection"
                },
                {
                    "id": "s0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0060",
            "sentence": "Therefore, seroconversion is defined as a post-vaccination titer of \u226520.",
            "startOffset": 24777,
            "title": "Plaque-reduction neutralization titer assay"
        },
        {
            "endOffset": 30227,
            "parents": [
                {
                    "id": "s0085",
                    "title": "Results"
                }
            ],
            "secId": "s0090",
            "sentence": "Baseline participant demographics, age, and BMI for the 51 participants are shown in Table 1.",
            "startOffset": 30134,
            "title": "Study participants"
        },
        {
            "endOffset": 34707,
            "parents": [
                {
                    "id": "s0085",
                    "title": "Results"
                },
                {
                    "id": "s0095",
                    "title": "Safety"
                }
            ],
            "secId": "s0105",
            "sentence": "There were no serious adverse events reported at any time during the study.",
            "startOffset": 34632,
            "title": "Unsolicited events"
        },
        {
            "endOffset": 14206,
            "parents": [],
            "refoffsets": {
                "b0015": {
                    "endOffset": 14205,
                    "startOffset": 14200
                },
                "b0020": {
                    "endOffset": 14205,
                    "startOffset": 14200
                }
            },
            "secId": "s0005",
            "sentence": "Among persons infected with WNV, the majority have subclinical infection, approximately 25% develop West Nile fever, and about 1 in 200 develops neuroinvasive disease, with manifestations including encephalitis, meningitis, and flaccid paralysis [3,4].",
            "startOffset": 13954,
            "title": "Introduction"
        },
        {
            "endOffset": 40895,
            "parents": [],
            "refoffsets": {
                "b0155": {
                    "endOffset": 40894,
                    "startOffset": 40890
                }
            },
            "secId": "s0135",
            "sentence": "Previous studies have demonstrated the role of complement in the development of protective WNV antibody responses and demonstrated that addition of complement enhances neutralization activity [31].",
            "startOffset": 40698,
            "title": "Discussion"
        },
        {
            "endOffset": 13871,
            "parents": [],
            "refoffsets": {
                "b0005": {
                    "endOffset": 13870,
                    "startOffset": 13867
                }
            },
            "secId": "s0005",
            "sentence": "WNV was first identified in the Western hemisphere in 1999 as a cluster of viral encephalitis cases in New York City [1].",
            "startOffset": 13750,
            "title": "Introduction"
        },
        {
            "endOffset": 24776,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0035",
                    "title": "Data collection"
                },
                {
                    "id": "s0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0060",
            "sentence": "For the purposes of determining seroconversion rates and GMT, antibody titers of <10 have been assumed to be 5 (one dilution step below the assay limit of detection).",
            "startOffset": 24610,
            "title": "Plaque-reduction neutralization titer assay"
        },
        {
            "endOffset": 38053,
            "parents": [
                {
                    "id": "s0085",
                    "title": "Results"
                },
                {
                    "id": "s0120",
                    "title": "Immunogenicity results"
                }
            ],
            "secId": "s0125",
            "sentence": "Following a single 4 mcg dose in the PP population, one subject (6%) seroconverted at days 15 and 29 and 15 days following a second dose of vaccine, seroconversion rates increased to 50% before declining thereafter (Table 3).",
            "startOffset": 37828,
            "title": "PRNT50 and complement-enhanced PRNT50 seroresponses"
        },
        {
            "endOffset": 34515,
            "parents": [
                {
                    "id": "s0085",
                    "title": "Results"
                },
                {
                    "id": "s0095",
                    "title": "Safety"
                }
            ],
            "secId": "s0105",
            "sentence": "The most common System Organ Classes among related non-serious adverse events were Gastrointestinal disorders (2 events in 1 mcg group, 2 events in 4 mcg group), of which Diarrhea was the most common (1 event in 1 mcg group, 1 event in 4 mcg group).",
            "startOffset": 34266,
            "title": "Unsolicited events"
        },
        {
            "endOffset": 32975,
            "parents": [
                {
                    "id": "s0085",
                    "title": "Results"
                },
                {
                    "id": "s0095",
                    "title": "Safety"
                }
            ],
            "secId": "s0100",
            "sentence": "In total, solicited symptoms were similar across the treatment groups.",
            "startOffset": 32905,
            "title": "Solicited events"
        },
        {
            "endOffset": 20330,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "The original study design included primary and secondary objectives, which comprised safety and immunogenicity outcomes, respectively.",
            "startOffset": 20196,
            "title": "Data collection"
        },
        {
            "endOffset": 14633,
            "parents": [],
            "refoffsets": {
                "b0040": {
                    "endOffset": 14632,
                    "startOffset": 14629
                }
            },
            "secId": "s0005",
            "sentence": "From 1999 through 2017, a total of 48,183 cases of WNV disease have been reported in the United States, including 22,999 cases of neuroinvasive disease and 2163 deaths [8].",
            "startOffset": 14461,
            "title": "Introduction"
        },
        {
            "endOffset": 18028,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "The HydroVax-001 vaccine is a West Nile virus-Kunjin strain, Vero cell tissue culture-derived, purified whole virion vaccine inactivated with 3% hydrogen peroxide.",
            "startOffset": 17865,
            "title": "Study product"
        },
        {
            "endOffset": 20835,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0035",
                    "title": "Data collection"
                }
            ],
            "secId": "s0040",
            "sentence": "To be conservative, the reactogenicity adverse events were collected on participant-completed memory aids for 14 days following each vaccination visit.",
            "startOffset": 20684,
            "title": "Safety"
        },
        {
            "endOffset": 36657,
            "parents": [
                {
                    "id": "s0085",
                    "title": "Results"
                }
            ],
            "secId": "s0120",
            "sentence": "Seroresponses were determined using the plaque reduction neutralization test 50% reduction (PRNT50), a complement-enhanced PRNT50 assay, and a WNV-specific enzyme linked immunosorbent assay (ELISA).",
            "startOffset": 36459,
            "title": "Immunogenicity results"
        },
        {
            "endOffset": 19780,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "The pharmacist concealed the contents of the syringe by wrapping the syringe barrel with an opaque tape or other equivalent material.",
            "startOffset": 19647,
            "title": "Vaccine administration and masking"
        },
        {
            "endOffset": 21393,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0035",
                    "title": "Data collection"
                }
            ],
            "secId": "s0040",
            "sentence": "These events were collected in a standard, systematic format using a graded scale based on functional assessment or magnitude of reaction.",
            "startOffset": 21255,
            "title": "Safety"
        },
        {
            "endOffset": 43066,
            "parents": [],
            "refoffsets": {
                "b0165": {
                    "endOffset": 43065,
                    "startOffset": 43061
                }
            },
            "secId": "s0135",
            "sentence": "It is unclear how long antiviral immunity after ChimeriVax-WN might be maintained [33].",
            "startOffset": 42979,
            "title": "Discussion"
        },
        {
            "endOffset": 35205,
            "parents": [
                {
                    "id": "s0085",
                    "title": "Results"
                },
                {
                    "id": "s0095",
                    "title": "Safety"
                }
            ],
            "secId": "s0110",
            "sentence": "One subject (2%) in the placebo group experienced a mild platelet decrease.",
            "startOffset": 35130,
            "title": "Clinical laboratory evaluations"
        },
        {
            "endOffset": 39099,
            "parents": [
                {
                    "id": "s0085",
                    "title": "Results"
                },
                {
                    "id": "s0120",
                    "title": "Immunogenicity results"
                }
            ],
            "secId": "s0130",
            "sentence": "Exploratory immunogenicity results as assessed by ELISA were more robust than those as assessed by PRNT50 and complement-enhanced PRNT50 assays (Table 4 for PP Population and Supplemental Table 7 for modified ITT Population).",
            "startOffset": 38874,
            "title": "ELISA seroresponses"
        },
        {
            "endOffset": 35258,
            "parents": [
                {
                    "id": "s0085",
                    "title": "Results"
                },
                {
                    "id": "s0095",
                    "title": "Safety"
                }
            ],
            "secId": "s0110",
            "sentence": "No severe abnormal hematology results were reported.",
            "startOffset": 35206,
            "title": "Clinical laboratory evaluations"
        },
        {
            "endOffset": 21036,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0035",
                    "title": "Data collection"
                }
            ],
            "secId": "s0040",
            "sentence": "Participants were also requested to measure their temperature at the same time each day or if they felt feverish and record the highest temperature for that day for 14 days following each vaccination.",
            "startOffset": 20836,
            "title": "Safety"
        },
        {
            "endOffset": 25634,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0035",
                    "title": "Data collection"
                },
                {
                    "id": "s0055",
                    "title": "Immunogenicity"
                }
            ],
            "refoffsets": {
                "b0160": {
                    "endOffset": 25633,
                    "startOffset": 25629
                }
            },
            "secId": "s0065",
            "sentence": "This cut-off has been used in previous studies for a range of other viruses [32].",
            "startOffset": 25553,
            "title": "ELISA"
        },
        {
            "endOffset": 33563,
            "parents": [
                {
                    "id": "s0085",
                    "title": "Results"
                },
                {
                    "id": "s0095",
                    "title": "Safety"
                }
            ],
            "secId": "s0105",
            "sentence": "Of the total unsolicited events, 11 (among 8 subjects) were considered related to the study product.",
            "startOffset": 33463,
            "title": "Unsolicited events"
        },
        {
            "endOffset": 45336,
            "parents": [],
            "secId": "s0135",
            "sentence": "At day 180, the investigators performed a third vaccination and this resulted in antibody titers that were greatly improved over the first or second dose of vaccine and suggests that our vaccine approach could likewise be improved if a third dose of vaccine was administered on a similar vaccination schedule.",
            "startOffset": 45027,
            "title": "Discussion"
        },
        {
            "endOffset": 26984,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0070",
                    "title": "Statistical analysis"
                }
            ],
            "secId": "s0075",
            "sentence": "Safety was assessed at all study days (days 1, 2, 4 and 15 post dose 1, and days 2, 4, 15, 29, 57, 180 and 365 post dose 2), and reactogenicity was assessed for 14 days after administration of each dose.",
            "startOffset": 26781,
            "title": "Safety"
        },
        {
            "endOffset": 32783,
            "parents": [
                {
                    "id": "s0085",
                    "title": "Results"
                },
                {
                    "id": "s0095",
                    "title": "Safety"
                }
            ],
            "secId": "s0100",
            "sentence": "The most frequently reported systemic events were headache (9 subjects, 21%) and fatigue (6 subjects, 14%).",
            "startOffset": 32676,
            "title": "Solicited events"
        },
        {
            "endOffset": 42093,
            "parents": [],
            "refoffsets": {
                "b0085": {
                    "endOffset": 42092,
                    "startOffset": 42085
                },
                "b0095": {
                    "endOffset": 42092,
                    "startOffset": 42085
                }
            },
            "secId": "s0135",
            "sentence": "A 3-dose WNV DNA vaccine, administered at 4 mg per dose, resulted in an average PRNT50 = 50 (range 16\u2013128) one month after the third immunization [17,19].",
            "startOffset": 41939,
            "title": "Discussion"
        },
        {
            "endOffset": 28548,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0070",
                    "title": "Statistical analysis"
                }
            ],
            "secId": "s0080",
            "sentence": "The geometric mean PRNT50 titer, complement-enhanced PRNT50 titer, and ELISA titer (GMT) and associated exact 95% confidence interval were calculated by treatment group at baseline, days 15 and 29 after the first vaccination and days 15, 29, 57, 180, and 365 after the second vaccination.",
            "startOffset": 28260,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 33779,
            "parents": [
                {
                    "id": "s0085",
                    "title": "Results"
                },
                {
                    "id": "s0095",
                    "title": "Safety"
                }
            ],
            "secId": "s0105",
            "sentence": "In this first-in-person clinical study, relatedness was assumed if there was a known temporal relationship between administration of the study product and the adverse event, and no alternate etiology was identified.",
            "startOffset": 33564,
            "title": "Unsolicited events"
        },
        {
            "endOffset": 29422,
            "parents": [
                {
                    "id": "s0085",
                    "title": "Results"
                }
            ],
            "secId": "s0090",
            "sentence": "One subject was randomized and enrolled but did not receive the first vaccination and was subsequently replaced.",
            "startOffset": 29310,
            "title": "Study participants"
        },
        {
            "endOffset": 44233,
            "parents": [],
            "refoffsets": {
                "b0125": {
                    "endOffset": 44154,
                    "startOffset": 44147
                },
                "b0130": {
                    "endOffset": 44154,
                    "startOffset": 44147
                },
                "b0135": {
                    "endOffset": 44154,
                    "startOffset": 44147
                }
            },
            "secId": "s0135",
            "sentence": "As an alternative to traditional formaldehyde-based vaccines, this novel hydrogen peroxide (H2O2) inactivation approach has been developed to produce a first-generation whole-virus vaccine against WNV [25\u201327] using a naturally attenuated (BSL2) Kunjin strain of West Nile virus (WNV-KV).",
            "startOffset": 43946,
            "title": "Discussion"
        },
        {
            "endOffset": 17849,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Subjects were followed to day 365 for safety and to assess vaccine immunogenicity.",
            "startOffset": 17767,
            "title": "Design and conduct of the clinical trial"
        },
        {
            "endOffset": 30372,
            "parents": [
                {
                    "id": "s0085",
                    "title": "Results"
                }
            ],
            "secId": "s0090",
            "sentence": "The mean age was 31.3 years and ranged from 18 years to 48 years.",
            "startOffset": 30307,
            "title": "Study participants"
        },
        {
            "endOffset": 39758,
            "parents": [
                {
                    "id": "s0085",
                    "title": "Results"
                },
                {
                    "id": "s0120",
                    "title": "Immunogenicity results"
                }
            ],
            "secId": "s0130",
            "sentence": "Increases in ELISA GMTs over baseline were not observed in the Hydro-Vax-001 1 mcg group.",
            "startOffset": 39669,
            "title": "ELISA seroresponses"
        },
        {
            "endOffset": 36143,
            "parents": [
                {
                    "id": "s0085",
                    "title": "Results"
                },
                {
                    "id": "s0095",
                    "title": "Safety"
                }
            ],
            "secId": "s0110",
            "sentence": "This subject had reported a mild glucose decrease of 65 mg/dL at baseline and glucose returned to normal levels by the next visit on day 4 post second vaccination.",
            "startOffset": 35980,
            "title": "Clinical laboratory evaluations"
        },
        {
            "endOffset": 21909,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0035",
                    "title": "Data collection"
                }
            ],
            "secId": "s0040",
            "sentence": "Resolution of an adverse event was defined as the return to pre-treatment status or stabilization of the condition with the expectation that it will remain chronic.",
            "startOffset": 21745,
            "title": "Safety"
        },
        {
            "endOffset": 22885,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0035",
                    "title": "Data collection"
                }
            ],
            "refoffsets": {
                "b0135": {
                    "endOffset": 22884,
                    "startOffset": 22880
                }
            },
            "secId": "s0050",
            "sentence": "Four days after each vaccination, blood samples were tested for WNV viremia using a standard virus plaque assay on Vero cells [27].",
            "startOffset": 22754,
            "title": "WNV viremia"
        },
        {
            "endOffset": 40331,
            "parents": [],
            "secId": "s0135",
            "sentence": "At the 1 mcg dose, HydroVax-001 was not immunogenic by PRNT50 seroconversion but we observed up to 41% seroconversion based on WNV-specific ELISA.",
            "startOffset": 40185,
            "title": "Discussion"
        },
        {
            "endOffset": 29787,
            "parents": [
                {
                    "id": "s0085",
                    "title": "Results"
                }
            ],
            "secId": "s0090",
            "sentence": "In the HydroVax-001 1 mcg group, one subject was excluded from the modified ITT and PP populations for not receiving any vaccinations, and three subjects were excluded from the PP population for not receiving both vaccinations.",
            "startOffset": 29560,
            "title": "Study participants"
        },
        {
            "endOffset": 42978,
            "parents": [],
            "secId": "s0135",
            "sentence": "The live-attenuated ChimeriVax-WN vaccine induced a robust antiviral antibody response with >96% seroconversion, but by 12 months post-vaccination the PRNT50 levels had declined to 58 for subjects between 41 and 64 years of age (PRNT50 = 116 for all subjects).",
            "startOffset": 42718,
            "title": "Discussion"
        },
        {
            "endOffset": 13953,
            "parents": [],
            "refoffsets": {
                "b0010": {
                    "endOffset": 13952,
                    "startOffset": 13949
                }
            },
            "secId": "s0005",
            "sentence": "Since then, WNV has spread rapidly west across the continental United States [2].",
            "startOffset": 13872,
            "title": "Introduction"
        },
        {
            "endOffset": 35851,
            "parents": [
                {
                    "id": "s0085",
                    "title": "Results"
                },
                {
                    "id": "s0095",
                    "title": "Safety"
                }
            ],
            "secId": "s0110",
            "sentence": "The potassium value normalized to 4.5 mmol/L at the next scheduled protocol visit, 7 days after the supplemental visit.",
            "startOffset": 35732,
            "title": "Clinical laboratory evaluations"
        },
        {
            "endOffset": 25763,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0035",
                    "title": "Data collection"
                },
                {
                    "id": "s0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0065",
            "sentence": "If a subject\u2019s baseline ELISA value was <200 and their follow-up visit ELISA value was >200, this was considered seroconversion.",
            "startOffset": 25635,
            "title": "ELISA"
        },
        {
            "endOffset": 23079,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0035",
                    "title": "Data collection"
                }
            ],
            "secId": "s0050",
            "sentence": "Briefly, undiluted serum samples were adsorbed in duplicate onto confluent Vero cell monolayers in 6-well tissue culture plates (0.20 mL per well, or 0.40 mL per sample) for 1 h at 37 \u00b0C/5%CO2.",
            "startOffset": 22886,
            "title": "WNV viremia"
        },
        {
            "endOffset": 46004,
            "parents": [],
            "refoffsets": {
                "b0185": {
                    "endOffset": 45713,
                    "startOffset": 45709
                }
            },
            "secId": "s0135",
            "sentence": "In a recent study [37], Quintel et al., have developed a site-directed, Fenton-type oxidation approach that leads to more efficient virus inactivation with improved retention of neutralizing epitopes and a greater than 100-fold improvement in vaccine-mediated WNV-specific neutralizing antibody responses in mice.",
            "startOffset": 45691,
            "title": "Discussion"
        },
        {
            "endOffset": 23655,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0035",
                    "title": "Data collection"
                }
            ],
            "secId": "s0050",
            "sentence": "If no plaques were visible for a sample, it was considered as having <2.5 PFU/mL (<1 PFU per 0.40 mL of sample tested).",
            "startOffset": 23536,
            "title": "WNV viremia"
        },
        {
            "endOffset": 17516,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Following a dose escalation design, the vaccine dose increased between groups from 1 mcg HydroVax-001 (group 1) to 4 mcg HydroVax-001 (group 2).",
            "startOffset": 17372,
            "title": "Design and conduct of the clinical trial"
        },
        {
            "endOffset": 25552,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0035",
                    "title": "Data collection"
                },
                {
                    "id": "s0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0065",
            "sentence": "Based on previous experience with the assay and human serum samples, a conservative \u201climit of detection\u201d cut-off of 200 ELISA units was utilized.",
            "startOffset": 25407,
            "title": "ELISA"
        },
        {
            "endOffset": 16044,
            "parents": [],
            "refoffsets": {
                "b0130": {
                    "endOffset": 16043,
                    "startOffset": 16039
                }
            },
            "secId": "s0005",
            "sentence": "Both young and aged mice immunized with H2O2-inactivated WNV-KV, formulated with aluminum hydroxide, demonstrated robust antiviral B and T cell immunity and protection in a stringent intracranial challenge model using a heterologous North American WNV strain [26].",
            "startOffset": 15780,
            "title": "Introduction"
        },
        {
            "endOffset": 30638,
            "parents": [
                {
                    "id": "s0085",
                    "title": "Results"
                },
                {
                    "id": "s0095",
                    "title": "Safety"
                }
            ],
            "secId": "s0100",
            "sentence": "A total of 33 subjects (66%) reported solicited events after either vaccination with HydroVax-001 WNV or placebo, with 26 subjects (52%) reporting at least one systemic symptom and 22 subjects (44%) reporting at least one local symptom.",
            "startOffset": 30402,
            "title": "Solicited events"
        },
        {
            "endOffset": 36799,
            "parents": [
                {
                    "id": "s0085",
                    "title": "Results"
                },
                {
                    "id": "s0120",
                    "title": "Immunogenicity results"
                }
            ],
            "secId": "s0125",
            "sentence": "All subjects enrolled were seronegative at baseline as determined by the PRNT50 assay.",
            "startOffset": 36713,
            "title": "PRNT50 and complement-enhanced PRNT50 seroresponses"
        },
        {
            "endOffset": 27184,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0070",
                    "title": "Statistical analysis"
                }
            ],
            "secId": "s0075",
            "sentence": "The analyses of safety data were primarily descriptive.",
            "startOffset": 27129,
            "title": "Safety"
        },
        {
            "endOffset": 18343,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Sodium Chloride Injection USP 0.9% as a sterile, nonpyrogenic, isotonic solution was used as the vaccine diluent and the placebo.",
            "startOffset": 18214,
            "title": "Study product"
        },
        {
            "endOffset": 30133,
            "parents": [
                {
                    "id": "s0085",
                    "title": "Results"
                }
            ],
            "secId": "s0090",
            "sentence": "In the HydroVax-001 4 mcg group, one subject was excluded from the modified ITT analysis population for not having pre- and post-baseline blood draws for the WNV assay, and four subjects were excluded from the PP population for not receiving both vaccinations (including the subject without pre- and post-baseline blood draws for the WNV assay).",
            "startOffset": 29788,
            "title": "Study participants"
        },
        {
            "endOffset": 37632,
            "parents": [
                {
                    "id": "s0085",
                    "title": "Results"
                },
                {
                    "id": "s0120",
                    "title": "Immunogenicity results"
                }
            ],
            "secId": "s0125",
            "sentence": "The complement-enhanced PRNT50 seroresponses paralleled the PRNT50.",
            "startOffset": 37565,
            "title": "PRNT50 and complement-enhanced PRNT50 seroresponses"
        },
        {
            "endOffset": 17263,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Subjects of childbearing potential were also required to have a negative pregnancy test on the date of screening and prior to each dose administration.",
            "startOffset": 17112,
            "title": "Design and conduct of the clinical trial"
        },
        {
            "endOffset": 41813,
            "parents": [],
            "secId": "s0135",
            "sentence": "At the 4 mcg dose, Hydro-Vax-001 induced a seroresponse in 13% of subjects at day 29 following a first dose with up to 75% of subjects seroconverting by day 29 following a second dose before declining thereafter.",
            "startOffset": 41601,
            "title": "Discussion"
        },
        {
            "endOffset": 44831,
            "parents": [],
            "refoffsets": {
                "b0180": {
                    "endOffset": 44830,
                    "startOffset": 44826
                }
            },
            "secId": "s0135",
            "sentence": "In a Phase I/II dose escalation study involving 320 subjects, WNV-specific neutralizing antibody titers were low after primary vaccination but appeared to increase to geometric mean titers of between 50 and 75 by day 56 (i.e., 28 days after 2nd dose) before declining to near baseline levels by day 180 post-vaccination [36].",
            "startOffset": 44506,
            "title": "Discussion"
        },
        {
            "endOffset": 26770,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0070",
            "sentence": "The per protocol (PP) population excludes subjects who did not receive both doses of study vaccine or who had major protocol deviations, such as receipt of non-study vaccines during the time frame prohibited by the protocol or receipt of the second study vaccination substantially out of window.",
            "startOffset": 26475,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 40534,
            "parents": [],
            "secId": "s0135",
            "sentence": "At the 4 mcg dose, HydroVax-001 was modestly immunogenic following a second dose of vaccine with 31% to 50% seroconversion identified by standard PRNT50 or by a complement-enhanced PRNT50, respectively.",
            "startOffset": 40332,
            "title": "Discussion"
        },
        {
            "endOffset": 18932,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0020",
                    "title": "Study product"
                }
            ],
            "secId": "s0025",
            "sentence": "At the time the preclinical toxicology study was performed, a 6 mcg/0.5 mL \u201chigh dose\u201d and a 1 mcg/0.5 mL \u201clow dose\u201d vaccine formulation was planned for this Phase I clinical trial.",
            "startOffset": 18751,
            "title": "Dose rationale"
        },
        {
            "endOffset": 32675,
            "parents": [
                {
                    "id": "s0085",
                    "title": "Results"
                },
                {
                    "id": "s0095",
                    "title": "Safety"
                }
            ],
            "secId": "s0100",
            "sentence": "Following Dose 2, 22 (51%) subjects reported any solicited symptom with 14 (33%) reporting a systemic symptom: 6 (35%) in the 1 mcg group, 4 (25%) in the 4 mcg group, and 4 (40%) in the placebo group.",
            "startOffset": 32475,
            "title": "Solicited events"
        },
        {
            "endOffset": 30306,
            "parents": [
                {
                    "id": "s0085",
                    "title": "Results"
                }
            ],
            "secId": "s0090",
            "sentence": "Overall, most subjects were female (73%), non-Hispanic (96%), and white (69%).",
            "startOffset": 30228,
            "title": "Study participants"
        },
        {
            "endOffset": 33315,
            "parents": [
                {
                    "id": "s0085",
                    "title": "Results"
                },
                {
                    "id": "s0095",
                    "title": "Safety"
                }
            ],
            "secId": "s0105",
            "sentence": "A total of 56 non-serious unsolicited adverse events were reported among 29 subjects during the period of enrollment through day 57 following the second vaccination, including among 10 subjects (50%) in the 1 mcg group, 11 subjects (55%) in the 4 mcg group, and 8 subjects (80%) in the placebo group (data not shown).",
            "startOffset": 32998,
            "title": "Unsolicited events"
        },
        {
            "endOffset": 21744,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0035",
                    "title": "Data collection"
                }
            ],
            "secId": "s0040",
            "sentence": "All SAEs were followed until resolution even if this extended beyond the study-reporting period.",
            "startOffset": 21648,
            "title": "Safety"
        },
        {
            "endOffset": 18750,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0020",
                    "title": "Study product"
                }
            ],
            "refoffsets": {
                "b0135": {
                    "endOffset": 18586,
                    "startOffset": 18582
                },
                "b0140": {
                    "endOffset": 18661,
                    "startOffset": 18654
                },
                "b0145": {
                    "endOffset": 18661,
                    "startOffset": 18654
                },
                "b0150": {
                    "endOffset": 18661,
                    "startOffset": 18654
                }
            },
            "secId": "s0025",
            "sentence": "Based on animal model evaluations of HydroVax-001 [27] and studies of other inactivated alum-adsorbed flavivirus vaccines [28\u201330], the antigen doses evaluated in this Phase 1 trial of HydroVax-001 were 1 mcg and 4 mcg.",
            "startOffset": 18532,
            "title": "Dose rationale"
        },
        {
            "endOffset": 21526,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0035",
                    "title": "Data collection"
                }
            ],
            "secId": "s0040",
            "sentence": "All unsolicited, non-serious AEs were documented from Study Visit 01 (day 1) through Study Visit 08 (day 57 post second vaccination).",
            "startOffset": 21393,
            "title": "Safety"
        },
        {
            "endOffset": 32112,
            "parents": [
                {
                    "id": "s0085",
                    "title": "Results"
                },
                {
                    "id": "s0095",
                    "title": "Safety"
                }
            ],
            "secId": "s0100",
            "sentence": "Following Dose 1, 29 (58%) subjects reported any solicited symptom with 22 (44%) reporting a systemic symptom: 10 (50%) in the 1 mcg group, 6 (30%) in the 4 mcg group, and 6 (60%) in the placebo group.",
            "startOffset": 31911,
            "title": "Solicited events"
        },
        {
            "endOffset": 35979,
            "parents": [
                {
                    "id": "s0085",
                    "title": "Results"
                },
                {
                    "id": "s0095",
                    "title": "Safety"
                }
            ],
            "secId": "s0110",
            "sentence": "A different subject experienced a severe reduction in glucose to 54 mg/dL on day 29 prior to the second vaccination with 4 mcg.",
            "startOffset": 35852,
            "title": "Clinical laboratory evaluations"
        },
        {
            "endOffset": 45026,
            "parents": [],
            "secId": "s0135",
            "sentence": "A range of vaccine doses (1.25, 2.5, 5, and 10 mcg/dose) was tested and no major improvement in antibody persistence was observed even after vaccination with a maximum dose of 10 mcg of vaccine.",
            "startOffset": 44832,
            "title": "Discussion"
        },
        {
            "endOffset": 34024,
            "parents": [
                {
                    "id": "s0085",
                    "title": "Results"
                },
                {
                    "id": "s0095",
                    "title": "Safety"
                }
            ],
            "secId": "s0105",
            "sentence": "None of the related unsolicited adverse events were considered severe; 2 events were considered moderate (1 in the 1 mcg group and 1 in the 4 mcg group); and 9 events were considered mild (3 in 1 mcg group, 5 in 4 mcg group 1 in placebo group).",
            "startOffset": 33780,
            "title": "Unsolicited events"
        },
        {
            "endOffset": 45690,
            "parents": [],
            "refoffsets": {
                "b0125": {
                    "endOffset": 45590,
                    "startOffset": 45586
                }
            },
            "secId": "s0135",
            "sentence": "The first published use of 3% peroxide for virus inactivation/vaccine development was described in 2012 [25] and several improvements in oxidation-based virus inactivation have been developed since that time.",
            "startOffset": 45482,
            "title": "Discussion"
        },
        {
            "endOffset": 16517,
            "parents": [],
            "secId": "s0005",
            "sentence": "In light of these promising results, HydroVax-001 WNV, a 3% hydrogen peroxide-inactivated, whole virion (WNV-Kunjin strain) vaccine, was administered as a two-dose intramuscular (IM) vaccine scheduled at a 28-day interval to assess safety and immunogenicity in humans.",
            "startOffset": 16249,
            "title": "Introduction"
        },
        {
            "endOffset": 29155,
            "parents": [
                {
                    "id": "s0085",
                    "title": "Results"
                }
            ],
            "secId": "s0090",
            "sentence": "A total of 96 subjects were screened to enroll 51 healthy male and non-pregnant females into this clinical trial between March 31, 2015 and November 20, 2015.",
            "startOffset": 28997,
            "title": "Study participants"
        },
        {
            "endOffset": 19216,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Study staff and investigators were not blinded to dose group.",
            "startOffset": 19155,
            "title": "Vaccine administration and masking"
        },
        {
            "endOffset": 22738,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0035",
                    "title": "Data collection"
                }
            ],
            "secId": "s0045",
            "sentence": "Urine was tested by dipstick at screening for glucose and protein and on day 29 after the first vaccination and day 15 after the second vaccination for glucose, protein, blood, and leukocyte esterase.",
            "startOffset": 22538,
            "title": "Laboratory safety data"
        },
        {
            "endOffset": 38568,
            "parents": [
                {
                    "id": "s0085",
                    "title": "Results"
                },
                {
                    "id": "s0120",
                    "title": "Immunogenicity results"
                }
            ],
            "secId": "s0125",
            "sentence": "Though limited in magnitude, a non-significant rise in GMT in the HydroVax-001 1mcg group was observed at day 29 post Dose 2, but only with the PRNT50 assay and not the complement-enhanced PRNT50 assay.",
            "startOffset": 38366,
            "title": "PRNT50 and complement-enhanced PRNT50 seroresponses"
        },
        {
            "endOffset": 21254,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0035",
                    "title": "Data collection"
                }
            ],
            "secId": "s0040",
            "sentence": "In addition, oral temperature, pulse and blood pressure were measured at screening, prior to each vaccination, and on day 4 and day 15 post each vaccination and performed at other study visits if clinically indicated.",
            "startOffset": 21037,
            "title": "Safety"
        },
        {
            "endOffset": 26218,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0070",
            "sentence": "The analysis populations including the safety population (SP) included all eligible subjects who received at least one dose of study vaccine.",
            "startOffset": 26077,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 33462,
            "parents": [
                {
                    "id": "s0085",
                    "title": "Results"
                },
                {
                    "id": "s0095",
                    "title": "Safety"
                }
            ],
            "secId": "s0105",
            "sentence": "None of the unsolicited adverse events were considered severe; 11 events (20%) were considered moderate; and 45 events (80%) were considered mild.",
            "startOffset": 33316,
            "title": "Unsolicited events"
        },
        {
            "endOffset": 20683,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0035",
                    "title": "Data collection"
                }
            ],
            "secId": "s0040",
            "sentence": "Solicited reactogenicity events were those adverse events known to typically occur following the administration of an inactivated vaccine.",
            "startOffset": 20545,
            "title": "Safety"
        },
        {
            "endOffset": 21997,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0035",
                    "title": "Data collection"
                }
            ],
            "secId": "s0040",
            "sentence": "Unsolicited AEs were assessed for relationship to study product (not related, related).",
            "startOffset": 21910,
            "title": "Safety"
        },
        {
            "endOffset": 35129,
            "parents": [
                {
                    "id": "s0085",
                    "title": "Results"
                },
                {
                    "id": "s0095",
                    "title": "Safety"
                }
            ],
            "secId": "s0110",
            "sentence": "Three subjects (6%), (1 in 1 mcg group, 2 in 4 mcg group) had mild hemoglobin decreases and 3 (6%), (1 in 1 mcg group, 2 in 4 mcg group) experienced a mild WBC increase.",
            "startOffset": 34960,
            "title": "Clinical laboratory evaluations"
        },
        {
            "endOffset": 35492,
            "parents": [
                {
                    "id": "s0085",
                    "title": "Results"
                },
                {
                    "id": "s0095",
                    "title": "Safety"
                }
            ],
            "secId": "s0110",
            "sentence": "Seventeen subjects (34%) (5 in 1 mcg group, 8 in 4 mcg group, 4 in placebo group) experienced an abnormal chemistry result considered related to dose administration by the blinded investigator including two with severe abnormalities.",
            "startOffset": 35259,
            "title": "Clinical laboratory evaluations"
        },
        {
            "endOffset": 39555,
            "parents": [
                {
                    "id": "s0085",
                    "title": "Results"
                },
                {
                    "id": "s0120",
                    "title": "Immunogenicity results"
                }
            ],
            "secId": "s0130",
            "sentence": "At the 4 mcg dose, Hydro-Vax-001 induced seroconversion in 13% of subjects at day 29 following a first dose and this increased to 75% of subjects seroconverting by day 29 following a second dose before declining thereafter with kinetics similar to the PRNT50 assays.",
            "startOffset": 39289,
            "title": "ELISA seroresponses"
        },
        {
            "endOffset": 18513,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "During storage, HydroVax-001 vials were kept in a lightproof container.",
            "startOffset": 18442,
            "title": "Study product"
        },
        {
            "endOffset": 19868,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "In addition, the subject was instructed to look away when the vaccine was administered.",
            "startOffset": 19781,
            "title": "Vaccine administration and masking"
        },
        {
            "endOffset": 38365,
            "parents": [
                {
                    "id": "s0085",
                    "title": "Results"
                },
                {
                    "id": "s0120",
                    "title": "Immunogenicity results"
                }
            ],
            "secId": "s0125",
            "sentence": "As expected, baseline GMTs as assessed by both the PRNT50 and complement-enhanced PRNT50 were negative.",
            "startOffset": 38262,
            "title": "PRNT50 and complement-enhanced PRNT50 seroresponses"
        },
        {
            "endOffset": 43541,
            "parents": [],
            "refoffsets": {
                "b0125": {
                    "endOffset": 43420,
                    "startOffset": 43413
                },
                "b0130": {
                    "endOffset": 43420,
                    "startOffset": 43413
                },
                "b0170": {
                    "endOffset": 43540,
                    "startOffset": 43533
                },
                "b0175": {
                    "endOffset": 43540,
                    "startOffset": 43533
                }
            },
            "secId": "s0135",
            "sentence": "The first licensed veterinary WNV vaccine was based on this approach, using a formalin-inactivated crude viral harvest of WNV-NY99, formulated with a squalene-based adjuvant, to induce protective immunity in horses as well as other animal models [25,26], and additional studies have provided evidence of efficacy for formalin-inactivation as a potential WNV vaccine [34,35].",
            "startOffset": 43167,
            "title": "Discussion"
        },
        {
            "endOffset": 24248,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0035",
                    "title": "Data collection"
                },
                {
                    "id": "s0055",
                    "title": "Immunogenicity"
                }
            ],
            "refoffsets": {
                "b0155": {
                    "endOffset": 24180,
                    "startOffset": 24176
                }
            },
            "secId": "s0060",
            "sentence": "Complement-enhanced PRNT50 assays were performed similar to prior descriptions [31] using human C1q (50 mcg/mL, Complement Technology, Inc, Tyler, TX).",
            "startOffset": 24097,
            "title": "Plaque-reduction neutralization titer assay"
        },
        {
            "endOffset": 25348,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0035",
                    "title": "Data collection"
                },
                {
                    "id": "s0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0065",
            "sentence": "The exact values are calculated via regression analysis (serum dilution vs. ELISA signal).",
            "startOffset": 25258,
            "title": "ELISA"
        },
        {
            "endOffset": 15133,
            "parents": [],
            "refoffsets": {
                "b0050": {
                    "endOffset": 14979,
                    "startOffset": 14972
                },
                "b0055": {
                    "endOffset": 14979,
                    "startOffset": 14972
                },
                "b0060": {
                    "endOffset": 14979,
                    "startOffset": 14972
                },
                "b0065": {
                    "endOffset": 14979,
                    "startOffset": 14972
                },
                "b0070": {
                    "endOffset": 14979,
                    "startOffset": 14972
                },
                "b0075": {
                    "endOffset": 14979,
                    "startOffset": 14972
                },
                "b0080": {
                    "endOffset": 14979,
                    "startOffset": 14972
                },
                "b0085": {
                    "endOffset": 14979,
                    "startOffset": 14972
                },
                "b0090": {
                    "endOffset": 14979,
                    "startOffset": 14972
                },
                "b0095": {
                    "endOffset": 14979,
                    "startOffset": 14972
                },
                "b0100": {
                    "endOffset": 15014,
                    "startOffset": 15010
                },
                "b0105": {
                    "endOffset": 15102,
                    "startOffset": 15095
                },
                "b0110": {
                    "endOffset": 15102,
                    "startOffset": 15095
                },
                "b0115": {
                    "endOffset": 15102,
                    "startOffset": 15095
                },
                "b0120": {
                    "endOffset": 15132,
                    "startOffset": 15128
                }
            },
            "secId": "s0005",
            "sentence": "These efforts include live, attenuated chimeric vaccines [10\u201316], DNA vectored vaccines [10\u201319], recombinant subunit vaccines [20], and a variety of protein vaccines including chemically inactivated whole virus [21\u201323] and virus-like particles [24].",
            "startOffset": 14884,
            "title": "Introduction"
        },
        {
            "endOffset": 22094,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0035",
                    "title": "Data collection"
                }
            ],
            "secId": "s0040",
            "sentence": "All AEs were graded for seriousness as per 21 CFR312.32 and severity (mild, moderate, or severe).",
            "startOffset": 21997,
            "title": "Safety"
        },
        {
            "endOffset": 23972,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0035",
                    "title": "Data collection"
                },
                {
                    "id": "s0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0060",
            "sentence": "The a priori immunogenicity objectives included assessing WNV-specific plaque reduction neutralization test (PRNT50) responses 29 days after a first dose and 57 days after a second dose of HydroVax-001 WNV vaccine given at doses of 1 mcg and 4 mcg.",
            "startOffset": 23724,
            "title": "Plaque-reduction neutralization titer assay"
        },
        {
            "endOffset": 31103,
            "parents": [
                {
                    "id": "s0085",
                    "title": "Results"
                },
                {
                    "id": "s0095",
                    "title": "Safety"
                }
            ],
            "secId": "s0100",
            "sentence": "The most commonly reported systemic symptoms were fatigue and headache, which were distributed similarly among all groups.",
            "startOffset": 30981,
            "title": "Solicited events"
        },
        {
            "endOffset": 31910,
            "parents": [
                {
                    "id": "s0085",
                    "title": "Results"
                },
                {
                    "id": "s0095",
                    "title": "Safety"
                }
            ],
            "secId": "s0100",
            "sentence": "Solicited events following Doses 1 and 2 are summarized in Supplemental Tables 3 and 4, respectively.",
            "startOffset": 31809,
            "title": "Solicited events"
        },
        {
            "endOffset": 39288,
            "parents": [
                {
                    "id": "s0085",
                    "title": "Results"
                },
                {
                    "id": "s0120",
                    "title": "Immunogenicity results"
                }
            ],
            "secId": "s0130",
            "sentence": "At the 1 mcg dose, Hydro-Vax-001 induced seroconversion in 18% of subjects at day 15 following a first dose increasing to 41% of the subjects responding by 15 days following a second dose.",
            "startOffset": 39100,
            "title": "ELISA seroresponses"
        },
        {
            "endOffset": 41938,
            "parents": [],
            "refoffsets": {
                "b0045": {
                    "endOffset": 41937,
                    "startOffset": 41934
                }
            },
            "secId": "s0135",
            "sentence": "Although a number of preclinical WNV vaccine approaches have been developed, few have proceeded to human clinical trials [9].",
            "startOffset": 41813,
            "title": "Discussion"
        },
        {
            "endOffset": 44329,
            "parents": [],
            "secId": "s0135",
            "sentence": "Hence, there are potential advantages with respect to vaccine manufacturing and vaccine safety.",
            "startOffset": 44234,
            "title": "Discussion"
        },
        {
            "endOffset": 43689,
            "parents": [],
            "secId": "s0135",
            "sentence": "From a clinical perspective, one concern for these formalin-inactivated WNV vaccine candidates is that they are based on pathogenic strains of WNV.",
            "startOffset": 43542,
            "title": "Discussion"
        },
        {
            "endOffset": 42286,
            "parents": [],
            "refoffsets": {
                "b0050": {
                    "endOffset": 42285,
                    "startOffset": 42278
                },
                "b0055": {
                    "endOffset": 42285,
                    "startOffset": 42278
                },
                "b0060": {
                    "endOffset": 42285,
                    "startOffset": 42278
                },
                "b0065": {
                    "endOffset": 42285,
                    "startOffset": 42278
                }
            },
            "secId": "s0135",
            "sentence": "Two chimeric live-attenuated vaccines, based on either dengue serotype 4 (rWN/DEN4\u039430) or YFV-17D (ChimeriVax-WN) backbones expressing WNV prM/Env proteins, have been tested in humans [10\u201313].",
            "startOffset": 42094,
            "title": "Discussion"
        },
        {
            "endOffset": 24976,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0035",
                    "title": "Data collection"
                },
                {
                    "id": "s0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0065",
            "sentence": "The protocol was amended to include an exploratory immunogenicity objective to assess WNV-specific ELISA responses.",
            "startOffset": 24861,
            "title": "ELISA"
        },
        {
            "endOffset": 27720,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0070",
                    "title": "Statistical analysis"
                }
            ],
            "secId": "s0075",
            "sentence": "The rate and exact 95% confidence intervals of related AEs in aggregate, and by MedDRA categories, were computed.",
            "startOffset": 27607,
            "title": "Safety"
        },
        {
            "endOffset": 32474,
            "parents": [
                {
                    "id": "s0085",
                    "title": "Results"
                },
                {
                    "id": "s0095",
                    "title": "Safety"
                }
            ],
            "secId": "s0100",
            "sentence": "Five subjects (10%) reported Grade 2 systemic events after the first vaccination: one subject (5%) in the HydroVax-001 1 mcg group reported muscle pain, two subjects (10%) in the HydroVax-001 4 mcg group reported nausea and one of those also reported fatigue, and two subjects (20%) in the placebo group reported headache and one of those also reported fatigue.",
            "startOffset": 32113,
            "title": "Solicited events"
        },
        {
            "endOffset": 35619,
            "parents": [
                {
                    "id": "s0085",
                    "title": "Results"
                },
                {
                    "id": "s0095",
                    "title": "Safety"
                }
            ],
            "secId": "s0110",
            "sentence": "One subject had a severe increase (5.8 mmol/L) in potassium on day 4 following a second mock vaccination in the placebo group.",
            "startOffset": 35493,
            "title": "Clinical laboratory evaluations"
        },
        {
            "endOffset": 15779,
            "parents": [],
            "refoffsets": {
                "b0130": {
                    "endOffset": 15778,
                    "startOffset": 15774
                }
            },
            "secId": "s0005",
            "sentence": "Further studies using WNV-Kunjin virus (WNV-KV), a naturally attenuated Lineage 1 WNV strain, expanded on these preliminary results [26].",
            "startOffset": 15642,
            "title": "Introduction"
        },
        {
            "endOffset": 27606,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0070",
                    "title": "Statistical analysis"
                }
            ],
            "secId": "s0075",
            "sentence": "Unsolicited AEs were coded by the Medical Dictionary for Regulatory Activities (MedDRA) for preferred term (PT) and system organ class (SOC).",
            "startOffset": 27465,
            "title": "Safety"
        },
        {
            "endOffset": 24382,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0035",
                    "title": "Data collection"
                },
                {
                    "id": "s0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0060",
            "sentence": "Seroconversion was defined as a 4-fold or greater increase in neutralizing antibody titer from baseline (prior to first vaccination).",
            "startOffset": 24249,
            "title": "Plaque-reduction neutralization titer assay"
        },
        {
            "endOffset": 24541,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0035",
                    "title": "Data collection"
                },
                {
                    "id": "s0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0060",
            "sentence": "Geometric mean PRNT50 titers were determined at days 15 and 29 after first vaccination and at days 15, 29, 57, 180, and 365 days after the second vaccination.",
            "startOffset": 24383,
            "title": "Plaque-reduction neutralization titer assay"
        },
        {
            "endOffset": 43166,
            "parents": [],
            "secId": "s0135",
            "sentence": "Inactivated whole virus vaccines remain an important class of vaccine candidates for WNV prevention.",
            "startOffset": 43066,
            "title": "Discussion"
        },
        {
            "endOffset": 28714,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0070",
                    "title": "Statistical analysis"
                }
            ],
            "secId": "s0080",
            "sentence": "For each study day, the number of subjects in the immunogenicity populations with available immunogenicity data at the particular study day was used in calculations.",
            "startOffset": 28549,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 14327,
            "parents": [],
            "refoffsets": {
                "b0025": {
                    "endOffset": 14326,
                    "startOffset": 14323
                }
            },
            "secId": "s0005",
            "sentence": "Neuroinvasive disease, more common among older adults, is associated with a case-fatality rate of approximately 10% [5].",
            "startOffset": 14207,
            "title": "Introduction"
        },
        {
            "endOffset": 40184,
            "parents": [],
            "secId": "s0135",
            "sentence": "This Phase 1 dose escalation study of HydroVax-001 demonstrated that HydroVax-001 was safe and well tolerated as there were no concerning safety signals.",
            "startOffset": 40031,
            "title": "Discussion"
        },
        {
            "endOffset": 16906,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "We enrolled healthy men and non-pregnant women aged 18 through 49 years in this prospective, placebo-controlled, observer-blind, dose-escalating, Phase 1 clinical vaccine trial.",
            "startOffset": 16729,
            "title": "Design and conduct of the clinical trial"
        },
        {
            "endOffset": 34265,
            "parents": [
                {
                    "id": "s0085",
                    "title": "Results"
                },
                {
                    "id": "s0095",
                    "title": "Safety"
                }
            ],
            "secId": "s0105",
            "sentence": "When comparing related events by study group, 4 events in 2 subjects (10%) were observed in the 1 mcg group, 6 events among 5 subjects (25%) were reported in the 4 mcg group and 1 event in 1 subject (10%) was described in the placebo group.",
            "startOffset": 34025,
            "title": "Unsolicited events"
        },
        {
            "endOffset": 38850,
            "parents": [
                {
                    "id": "s0085",
                    "title": "Results"
                },
                {
                    "id": "s0120",
                    "title": "Immunogenicity results"
                }
            ],
            "secId": "s0125",
            "sentence": "Results in the modified ITT analysis were similar (Supplemental Tables 5 and 6).",
            "startOffset": 38770,
            "title": "PRNT50 and complement-enhanced PRNT50 seroresponses"
        },
        {
            "endOffset": 29559,
            "parents": [
                {
                    "id": "s0085",
                    "title": "Results"
                }
            ],
            "secId": "s0090",
            "sentence": "The subjects excluded and analysis populations are illustrated and described in a CONSORT flow diagram, Fig. 1 and Supplemental Table 1.",
            "startOffset": 29423,
            "title": "Study participants"
        },
        {
            "endOffset": 17766,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Within each dosing group subjects were randomized 4:1 to receive either HydroVax-001 or placebo as a two dose series delivered intramuscularly on days 1 and 29.",
            "startOffset": 17606,
            "title": "Design and conduct of the clinical trial"
        },
        {
            "endOffset": 14883,
            "parents": [],
            "refoffsets": {
                "b0045": {
                    "endOffset": 14882,
                    "startOffset": 14879
                }
            },
            "secId": "s0005",
            "sentence": "However, since the introduction of WNV into the United States in 1999, significant research efforts have been expended to create a viable vaccine for disease prevention in humans [9].",
            "startOffset": 14700,
            "title": "Introduction"
        }
    ],
    "docId": "S0264410X18316992",
    "metadata": {
        "asjc": [
            "1313",
            "2400",
            "2725",
            "2739",
            "3400"
        ],
        "authors": [
            {
                "email": "chris.woods@duke.edu",
                "first": "Christopher W.",
                "initial": "C.W.",
                "last": "Woods"
            },
            {
                "email": null,
                "first": "Ana M.",
                "initial": "A.M.",
                "last": "Sanchez"
            },
            {
                "email": null,
                "first": "Geeta K.",
                "initial": "G.K.",
                "last": "Swamy"
            },
            {
                "email": null,
                "first": "Micah T.",
                "initial": "M.T.",
                "last": "McClain"
            },
            {
                "email": null,
                "first": "Lynn",
                "initial": "L.",
                "last": "Harrington"
            },
            {
                "email": null,
                "first": "Debra",
                "initial": "D.",
                "last": "Freeman"
            },
            {
                "email": null,
                "first": "Elizabeth A.",
                "initial": "E.A.",
                "last": "Poore"
            },
            {
                "email": null,
                "first": "Dawn K.",
                "initial": "D.K.",
                "last": "Slifka"
            },
            {
                "email": null,
                "first": "Danae E.",
                "initial": "D.E.",
                "last": "Poer DeRaad"
            },
            {
                "email": null,
                "first": "Ian J.",
                "initial": "I.J.",
                "last": "Amanna"
            },
            {
                "email": null,
                "first": "Mark K.",
                "initial": "M.K.",
                "last": "Slifka"
            },
            {
                "email": null,
                "first": "Shu",
                "initial": "S.",
                "last": "Cai"
            },
            {
                "email": null,
                "first": "Venus",
                "initial": "V.",
                "last": "Shahamatdar"
            },
            {
                "email": null,
                "first": "Michael R.",
                "initial": "M.R.",
                "last": "Wierzbicki"
            },
            {
                "email": null,
                "first": "Cyrille",
                "initial": "C.",
                "last": "Amegashie"
            },
            {
                "email": null,
                "first": "Emmanuel B.",
                "initial": "E.B.",
                "last": "Walter"
            }
        ],
        "doi": "10.1016/j.vaccine.2018.12.026",
        "firstpage": "4222",
        "issn": "0264410X",
        "keywords": [
            "Phase 1",
            "Vaccine",
            "West Nile virus"
        ],
        "lastpage": "4230",
        "openaccess": "Full",
        "pub_year": 2019,
        "subjareas": [
            "BIOC",
            "IMMU",
            "MEDI",
            "VETE"
        ],
        "title": "An observer blinded, randomized, placebo-controlled, phase I dose escalation trial to evaluate the safety and immunogenicity of an inactivated West Nile virus Vaccine, HydroVax-001, in healthy adults"
    }
}